At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the August 2026 edition.

The IMF team of medical editors has provided overviews of key studies. Yet, we encourage you to visit the actual articles in the journals for full details and to increase your understanding. Check the IMF Newsroom monthly for updates like this one.

In the Journals (Key Myeloma Research in August 2026)

Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia

Source

B. Reardon, I. Kerridge, and T. Armytage, “ Real-World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia.” Asia- Pacific Journal of Clinical Oncology (2026): . https://doi.org/10.1111/ajco.70143 August 1, 2026. 

Overview

This retrospective study evaluated real-world treatment patterns between 2018 and 2023 and survival outcomes among patients receiving daratumumab-based therapy in two regional tertiary centers. Most patients received a combination of daratumumab, bortezomib, and dexamethasone (60%, 32). Daratumumab-based combinations were feasible in a regional setting and yielded meaningful clinical outcomes in an older cohort with a high proportion of adverse cytogenetics. 

High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients

Source

Hwa YL, Jevremovic D, Pak K, Kapoor P, Visram A, Gertz MA, et al. High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients. Br J Haematol. 2026; 00: 1–7. https://doi.org/10.1111/bjh.70697 August 2, 2026. 

Overview

Iron deficiency (ID) is often overlooked in patients with haematological malignancies due to other potential aetiologies. Although anemia is a common haematological toxicity associated with daratumumab, the contribution of iron deficiency (ID) in MM patients has not been systematically investigated. These findings identify a marked clinical signal of ID among NDMM patients receiving daratumumab-based treatment. 

Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta- Analysis of Efficacy and Safety

Source

Qi, J., Park, D., Shah, P., & Akhtari, M. (2026). Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta- Analysis of Efficacy and Safety. Hematology Reports, 18(4), 54. https://doi.org/10.3390/hematolrep18040054 August 2, 2026. 

Overview

Although prior analyses have summarized teclistamab outcomes, some have included combination regimens or broader comparative studies. Given the expanding real-world experience with teclistamab, we conducted a systematic review and meta-analysis focused on teclistamab monotherapy in relapsed/refractory multiple myeloma (RRMM). However, severe infections and hematologic toxicities remain important clinical considerations, supporting the need for close monitoring, infection prevention, and supportive care during therapy. 

Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study

Source

Zhao, J., Bai, Q., Qiu, Q., Song, J., Kong, S., Zhu, K., Zhang, Y., Li, S., Ma, Y., Zhang, L., & Qin, X. (2026). Clinical Characteristics and Prognostic Analysis of Extramedullary Disease in Multiple Myeloma: A 15-Year Retrospective Cohort Study. Cancers, 18(15), 2484. https://doi.org/10.3390/cancers18152484 August 2, 2026. 

Overview

Extramedullary disease (EMD) in multiple myeloma (MM) is associated with poor prognosis, yet the clinical distinctions between bone-related EMD (bEMD) and soft tissue-associated EMD (sEMD) remain incompletely characterized. Researchers retrospectively analyzed 118 patients with MM and EMD treated at a single center from 2011 to 2025, including 72 bEMD and 46 sEMD cases. The proposed risk score, based on routinely available clinical parameters, effectively identifies high-risk patients at initial diagnosis and may guide individualized treatment strategies. 

Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma

Source

Herman van Besien, Gwynne Ozkan, Neela Easton, Tobias Tix, Mohammad Alhomoud, Roni Shouval, Kai Rejeski, Samuel Yamshon; Non-ICANS neurologic toxicity after BCMA CAR-T therapy: a systematic review and meta-analysis of 4630 patients with multiple myeloma. Blood Adv 2026; 10 (15): 5413–5425. doi: https://doi.org/10.1182/bloodadvances.2026019617 August 3, 2026. 

Overview

Although CAR-T–associated cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome (ICANS) are well characterized, non- ICANS neurologic toxicities (NINTs) remain poorly defined, with limited data regarding incidence and risk factors. B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR-T) therapies have drastically improved outcomes for patients with relapsed or refractory multiple myeloma. Standardized definitions and improved reporting of NINTs are needed to better characterize risk and inform surveillance strategies. 

Monoclonal gammopathy of clinical significance: a guide for nephrologists

Source

Patrick Hofmann, Sujal I Shah, Helmut G Rennke, Rahel Schwotzer, David B Sykes, Nelson Leung, Raad B Chowdhury, Monoclonal gammopathy of clinical significance: a guide for nephrologists, Nephrology Dialysis Transplantation, 2026;, gfag173, https://doi.org/10.1093/ndt/gfag173 August 3, 2026. 

Overview

In this review, researchers focus on monoclonal gammopathy of clinical significance (MGCS) entities beyond standard monoclonal gammopathy of renal significance (MGRS). MGRS and provide a mechanism-based classification centered on the pathogenic nature of the paraprotein rather than on clonal disease burden. Even in patients with overt plasma cell neoplasms such as multiple myeloma, the monoclonal antibody is often a marker of disease burden but not pathogenic except in light chain cast nephropathy. The researchers highlight MGCS entities of relevance to nephrologists, including POEMS syndrome, TEMPI syndrome, monoclonal gammopathy-associated systemic capillary leak syndrome, and hematologic autoantibody-mediated disorders. 

Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study

Source

Yin, J., Yu, S., Wu, H., Zhou, X., Li, X., Yuan, C., … Zhong, Y. (2026). Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study. Annals of Medicine, 58(1). https://doi.org/10.1080/07853890.2026.2703403 August 3, 2026. 

Overview

This study aims to evaluate the efficacy and safety of selinexor combined with bortezomib, lenalidomide, and dexamethasone (the XVRd regimen) for newly diagnosed multiple myeloma (NDMM) patients with high-risk features. This single-arm, open-label, prospective observational study recruited patients between August 2022 and November 2024. Survival analysis demonstrated a median PFS of 16.2 months (95% CI, 14.6–NA), a 1-year PFS rate of 89% (95% CI, 0.78–1), and unreached median overall survival (OS). 

DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma

Source

Maria Eugenia Gallo Cantafio, Noemi Puccio, Roberta Torcasio, Ilenia Valentino, Ludovica Ganino, Yuanyuan Jin, Anil Aktas Samur, Pierpaolo Murfone, Alessia Gallo, Mehmet K. Samur, Nicola Cuscino, Cesarina Giallongo, Ida Daniela Perrotta, Alessia Ciarrocchi, Federico Tallarigo, Ernestina Marianna De Francesco, Davide Barbuto, Ross David Jansen-van Vuuren, Luka Jedlovnik, Danchen Wu, Enrica Antonia Martino, Daniele Tibullo, Francesco Di Raimondo, Massimo Gentile, Antonino Neri, Stephen L. Archer, Eugenio Morelli, Nikhil C. Munshi, Giuseppe Viglietto, Mariateresa Fulciniti, Nicola Amodio; DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma. Blood 2026; blood.2025030349. doi: https://doi.org/10.1182/blood.2025030349 August 3, 2026. 

Overview

Using ultrastructural analyses, we reveal that MM cells display a highly fragmented mitochondrial network, a phenotype further exacerbated in both cell lines and primary MM cells resistant to proteasome inhibitors. Transcriptomic profiling across multiple patient-derived datasets consistently demonstrated upregulation of the DNM1L gene, which encodes the mitochondrial fission GTPase DRP1, particularly in relapsed and refractory MM, and revealed a significant association with inferior overall survival. Altogether, these findings establish aberrant mitochondrial fission as a pathogenic hallmark of MM and highlight DRP1 inhibition as a promising therapeutic approach, especially for relapsed or refractory disease. 

Infection Prevention and Management in Patients Living With Multiple Myeloma

Source

Shenoy S, Faiman B, Catamero D. Infection Prevention and Management in Patients Living With Multiple Myeloma. Clin J Oncol Nurs. 2026 Aug 3;30(4):E60-E66. doi: 10.1188/26.CJON.E60-E66. 

Overview

This article explores the complex landscape of infection in patients with MM, highlighting nurse responsibilities in early detection and management. Infection is a leading cause of death and a significant cause of morbidity in patients living with MM. By fostering competence through education, supporting autonomy through structured transitions of care, and maintaining relatedness through the patient–nurse relationship, oncology nurses can mitigate the infection risks associated with modern MM therapy. 

Non-covalent dual HDAC6/proteasome inhibitors with anti-multiple myeloma activity

Source

Yanmei Zhao, Xi Zou, Yidan Shao, Jingjing Sun, Tingting Shi, Yunling Ke, Rangxiao Zhuang, Non-covalent dual HDAC6/proteasome inhibitors with anti-multiple myeloma activity, Bioorganic & Medicinal Chemistry, 2026, 118762, ISSN 0968- 0896, https://doi.org/10.1016/j.bmc.2026.118762. August 3, 2026. 

Overview

A systematic comparison of different zinc-binding groups (ZBGs) within a non-covalent scaffold has been lacking. This marked shift is consistent with the limited membrane permeability frequently associated with polar peptidomimetic scaffolds, and it underscores a key limitation that must be addressed in future optimization efforts. 

Cardiovascular toxicity during treatment for multiple myeloma in a real-world cohort: incidence and baseline predictors

Source

L Lorenzo Alves, E Andrade, T Branco, J Goncalves, B Viana, M Rocha, S Amorim, M Paiva, R Rodrigues, Cardiovascular toxicity during treatment for multiple myeloma in a real-world cohort: incidence and baseline predictors, European Heart Journal Supplements, Volume 28, Issue Supplement_8, August 2026, suag097.191, https://doi.org/10.1093/eurheartjsupp/suag097.191 

Overview

This study aims to quantify the incidence of clinically relevant cardiovascular events during anti-myeloma treatment and explore baseline factors associated with risk. Cardiovascular toxicity is increasingly recognised in patients receiving contemporary therapy for multiple myeloma, yet real-world estimates and predictors remain incompletely characterised. Larger cohorts are warranted to confirm these findings and refine risk stratification. 

Evaluating the cardiovascular risk profiles of multiple myeloma patients before and 1 year after autologous stem cell transplant

Source

A De Boer, M Ebeid, J Tay, G T Gyenes, I Sandhu, K Y Wu, S L Koshman, Evaluating the cardiovascular risk profiles of multiple myeloma patients before and 1 year after autologous stem cell transplant, European Heart Journal Supplements, Volume 28, Issue Supplement_8, August 2026, suag097.077, https://doi.org/10.1093/eurheartjsupp/suag097.077 

Overview

This study aims to characterize baseline CV risk profiles in TEMM patients using commonly used risk tools, and to evaluate CV risk factor assessment and control before and one year after ASCT. Transplant-eligible multiple myeloma (TEMM) patients undergoing autologous stem cell transplant (ASCT) are at elevated risk of cardiovascular (CV) events. Substantial gaps in CV risk assessment and longitudinal risk factor control underscore the need for structured, multidisciplinary cardio-oncology pathways to support surveillance and preventive care before and after ASCT. 

Baseline cardiovascular risk stratification in multiple myeloma: a simple clinical score outperforming established risk models

Source

L Lorenzo Alves, T Branco, E Andrade, S Amorim, M Paiva, R Rodrigues, Baseline cardiovascular risk stratification in multiple myeloma: a simple clinical score outperforming established risk models, European Heart Journal Supplements, Volume 28, Issue Supplement_8, August 2026, suag097.116, https://doi.org/10.1093/eurheartjsupp/suag097.116 

Overview

This study aims to derive a simple baseline clinical risk score for cardiovascular events during multiple myeloma treatment and compare its discriminative performance with HFA-ICOS risk class, R-MCI class, ISS and R-ISS. Researchers performed a retrospective analysis of a real-world cohort of patients with multiple myeloma. This pragmatic approach may support targeted cardio-oncology surveillance at treatment initiation. 

Daratumumab therapy in AL amyloidosis with or without multiple myeloma and cardiac response

Source

R Coderre, H Gonzalez Bonilla, F Buadi, A Dispenzieri, M Gertz, M Grogan, E L I Mutchtar, B A Boilson, Daratumumab therapy in AL amyloidosis with or without multiple myeloma and cardiac response, European Heart Journal Supplements, Volume 28, Issue Supplement_8, August 2026, suag097.063, https://doi.org/10.1093/eurheartjsupp/suag097.063 

Overview

AL amyloidosis and multiple myeloma are plasma cell dyscrasias characterized by excess light-chain production leading to cardiac amyloid deposition and organ dysfunction. This study aims to evaluate the long-term effects of daratumumab therapy on cardiac biomarkers and myocardial amyloid burden, assessed by artificial intelligence- based electrocardiographic (AI-ECG) and echocardiographic measures, in patients with AL amyloidosis and cardiac involvement. These findings support the hypothesis that sustained suppression of pathogenic light-chain production may permit gradual improvement in amyloid cardiomyopathy over time. 

Prospective echocardiographic evaluation of systolic and diastolic cardiac function following anti-bcma car-t therapy in patients with multiple myeloma

Source

Y Orihara, M Asakura, I Sunayama, S Hayashi, K Shimizu, J Ohno, E Manabe, M Oboshi, K D Min, M Ishihara, Prospective echocardiographic evaluation of systolic and diastolic cardiac function following anti-bcma car-t therapy in patients with multiple myeloma, European Heart Journal Supplements, Volume 28, Issue Supplement_8, August 2026, suag097.159, https://doi.org/10.1093/eurheartjsupp/suag097.159 

Overview

These researchers have previously reported prospective data on cardiac function following CAR-T therapy in patients with diffuse large B-cell lymphoma. However, to date, limited prospective studies have evaluated changes in cardiac function after CAR-T therapy in patients with MM. These findings suggest that post–CAR-T therapy–related cardiac dysfunction in MM may be limited and largely reversible. 

Prognostic utility of natriuretic peptides and incremental value of the HFA-ICOS risk score in patients with multiple myeloma

Source

N Nakanishi, M Akagi, M Yamamoto, T Nakashima, K Tsujita, Prognostic utility of natriuretic peptides and incremental value of the HFA-ICOS risk score in patients with multiple myeloma, European Heart Journal Supplements, Volume 28, Issue Supplement_8, August 2026, suag097.048, https://doi.org/10.1093/eurheartjsupp/suag097.048 

Overview

The Heart Failure Association– International Cardio-Oncology Society (HFA-ICOS) risk score has been proposed as a comprehensive assessment tool; however, it requires multifactorial evaluation and has insufficient external validation. This retrospective cohort study included consecutive patients who initiated first-line treatment for MM between March 2015 and May 2025. These findings support the use of B-type natriuretic peptide (BNP) levels as an efficient tool for risk stratification in patients with MM. 

C-Reactive Protein-to-Albumin Ratio and Its Association with Inflammatory and Renal Parameters in Multiple Myeloma

Source

Odabasi Giden, A. (2026). C-Reactive Protein-to-Albumin Ratio and Its Association with Inflammatory and Renal Parameters in Multiple Myeloma. Hemato, 7(3), 26. https://doi.org/10.3390/hemato7030026 August 4, 2026. 

Overview

Multiple myeloma (MM) is a hematological malignancy characterized by systemic inflammation and frequent renal involvement. Patients were stratified into low and high CAR groups based on the median value (0.13). The observed findings, particularly regarding renal outcomes, should be interpreted with caution. 

Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare

Source

Oyinbo, A. G., Castaneda-Avila, M. A., Baek, J., Tisminetzky, M., Ramanathan, M., Lapane, K. L., & Epstein, M. M. (2026). Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare. Leukemia & Lymphoma, 1–11. https://doi.org/10.1080/10428194.2026.2711165 August 4, 2026. 

Overview

This study examined the association between multimorbidity patterns and survival in patients with multiple myeloma (2007–2017) using SEER-Medicare (n = 7281). Researchers determined survival differences between patients with low severity multimorbidity, concurrent psychiatric/musculoskeletal disorders, and concurrent cardiometabolic/multisystem impairments. The findings suggest that older adults with an elevated multimorbidity burden at diagnosis with multiple myeloma have poor survival outcomes and necessitate the development of health interventions to improve their cancer prognosis. 

A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data

Source

Breskin, A., Shokoohi, M., Suero, B. et al. A mortality model for relapsed or refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data. Ann Hematol (2026). https://doi.org/10.1007/s00277-026- 07200-z August 4, 2026. 

Overview

This study evaluated the feasibility of modeling mortality in RWD for relapsed/refractory multiple myeloma (RRMM) to replicate patient exclusion (LE < 6 months) for application in an external control arm study. Patients with limited life expectancy (LE) are often excluded from oncology trials based on subjective judgment, posing a challenge when contextualizing trial findings with real-world data (RWD). The de novo model exhibited strong discrimination performance but low F1 score, suggesting it may be useful to identify patients at highest risk who may be least likely to meet trial LE criteria. 

The Myeloma Risk Variant of TNFRSF13B Shows Reduced NF-κB Signalling Activity in HEK293 Cells

Source

R. M. Chen, J. L. Ludgate, R. J. Weeks, H. E. Cunliffe, A. G. Dohan, and I. M. Morison, “ The Myeloma Risk Variant of TNFRSF13B Shows Reduced NF-κB Signalling Activity in HEK293 Cells,” European Journal of Haematology (2026): 1–6, https://doi.org/10.1111/ejh.70283. August 4, 2026. 

Overview

Using HEK293 cells, NF-κB signalling of the variant and wild-type forms of TACI was measured by using an NF-κB-luciferase reporter assay and by quantifying NF-κB p65 subcellular localisation. This suggests an indirect effect of TACI P205L on the increased risk of myeloma. 

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences

Source

Quaife, M., Jimenez-Moreno, C., Gros Otero, B., Asra, A., Gupta-Werner, N., Gries, K. S., … Bathija, S. (2026). Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences. Future Oncology, 1–13. https://doi.org/10.1080/14796694.2026.2710562 August 4, 2026. 

Overview

This study aims to understand disease perceptions and treatment preferences of patients with high-risk smoldering multiple myeloma (HR-SMM) or multiple myeloma (MM) that recently progressed from HR-SMM, and to estimate the minimum progression-free survival (min- PFS) required to accept the treatment burden. This mixed-study interviewed 50 patients (HR-SMM and MM 1:1) from the USA, France, Italy, and Spain. Researchers concluded that tRF-17-8SPOL52 activates autophagy by inhibiting RUBCN in an Ago-dependent manner, which in turn leads to bortezomib resistance in myeloma. 

Laboratory characteristics of direct antiglobulin test–positive anemia in patients with newly diagnosed multiple myeloma

Source

Yutong Zheng, YanTian Zhao, Di Wu, Hong Zong, Hong Huo, ChuanYing Geng, Sha Li, YongQi He, YinChu Liu, HongShuai Li, JunQin Liu, YaJun Zhao, Xin Liu, Juan Lv, Laboratory characteristics of direct antiglobulin test–positive anemia in patients with newly diagnosed multiple myeloma, Laboratory Medicine, Volume 57, Issue 5, September 2026, lmag044, https://doi.org/10.1093/labmed/lmag044 August 4, 2026. 

Overview

This study retrospectively characterized the laboratory features of direct antiglobulin test (DAT)–positive anemia in newly diagnosed multiple myeloma (MM) and explored associated immunologic alterations to better understand MM-related immune dysregulation. We enrolled 77 patients with newly diagnosed MM admitted to our hospital between 2021 and 2025. Flow cytometric analysis showed increased T-cell–related parameters, particularly CD8-positive T cells, in the DAT-positive group, whereas reduced natural killer–cell and B- cell counts were more common in the DAT-negative group. 

Increased Risk of Infections and Mortality Following Fractures in Multiple Myeloma: A Nationwide Population-Based Retrospective Cohort Study

Source

C.-C. Lee, W.-Y. Huang, Y.-F. Chen, I.-S. Cheng, and K.-Y. Huang, “Increased Risk of Infections and Mortality Following Fractures in Multiple Myeloma: A Nationwide Population-Based Retrospective Cohort Study,” Health Science Reports 9 (2026): e72989, https://doi.org/10.1002/hsr2.72989. August 4, 2026. 

Overview

Thsi study aims to determine whether patients with MM face higher risks of hospitalized infections and long-term all-cause mortality after a first fracture than non-MM fracture patients at the population level. Researchers performed a nationwide retrospective cohort study using Taiwan National Health Insurance Research Database from 2001 to 2019. These findings support early multidisciplinary post-fracture care, including infection surveillance and prevention, in MM patients. 

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype

Source

Alana L. Keller, Kady A. Dennis, Denis J. Ohlstrom, Sarah E. Parzych, Zachary J. Walker, Amanda J. Novak, Catherine Pham-Danis, Tanisha N. Medha, Jeremy T. Rahkola, Meher P. Boorgula, M. Eric Kohler, Daniel W. Sherbenou; Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype. Cancer Immunol Res 1 August 2026; 14 (8): 1307–1321. https://doi.org/10.1158/2326-6066.CIR-25-1068 August 4, 2026. 

Overview

This study aims to better understand this treatment resistance, researchers examined multiple myeloma cells that persisted after these treatments and consistently observed CD45 upregulation as part of a resistance program. Bone marrow samples were treated ex vivo with BCMA CAR T cells, TCE antibodies (elranatamab, SAR442257), or activated T cells and analyzed via flow cytometry. These findings suggest that T cell–redirecting therapy (TCRT) drives an immunoevasive phenotype defined by CD45 upregulation and immune checkpoint activation, supporting combination strategies of TCRT with checkpoint inhibitors to overcome resistance in relapsed/refractory multiple myeloma. 

Prognostic and biological significance of MRPL13 in multiple myeloma: evidence from multi-cohort, single-cell analyses

Source

Liu W, Yan C, Wu H, Wu C, Cai Z, Wang Z, Zhuang W, Li M and Guo J (2026) Prognostic and biological significance of MRPL13 in multiple myeloma: evidence from multi-cohort, single-cell analyses. Front. Oncol. 16:1880529. doi: 10.3389/fonc.2026.1880529 August 4, 2026. 

Overview

Event-free survival (EFS) analysis was performed in the GSE24080 cohort, and progression-free survival (PFS) analysis was conducted in the GSE136337 cohort. We further analyzed single-cell transcriptomic profiles of 74,986 cells from 24 MM patients to delineate the expression landscape of MRPL13 across distinct cellular populations and functional subclusters and to assess its relationship with the immune microenvironment. Silencing MRPL13 inhibited proliferation and induced G0/G1 arrest.MRPL13 predicts poor prognosis and promotes MM progression through metabolic and immune regulation, supporting its potential as a prognostic biomarker and therapeutic target. 

Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities

Source

Jiang W, Xu L, Zhu C, Bai G, Peng S and Ma N (2026) Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities. Front. Oncol. 16:1897942. doi: 10.3389/fonc.2026.1897942 August 4, 2026. 

Overview

Ferroptosis, an iron-dependent form of regulated cell death characterized by excessive lipid peroxidation, has emerged as a potential therapeutic target in cancer and is increasingly implicated in MM biology. Nevertheless, current knowledge is derived predominantly from preclinical studies, and successful clinical translation will require improved tumor selectivity, rigorous safety evaluation, and biomarker-guided patient stratification. Biomarker-guided early-phase clinical studies should be pursued only after reproducible efficacy and an acceptable safety profile have been demonstrated in clinically relevant preclinical models to determine whether ferroptosis modulation can ultimately provide meaningful therapeutic benefits for patients with MM. 

Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis

Source

Y. Pan, Y. Wang, Y. Xiong, P. Li, C. Yu, and P. Liu, “Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis,” Hematological Oncology (2026): e70234, https://doi.org/10.1002/hon.70234. August 4, 2026. 

Overview

Minimal residual disease (MRD) is the standard for deep response assessment in multiple myeloma but requires bone marrow sampling. Whether early serum free light chain (sFLC) response provides independent prognostic information in real-world, predominantly non- transplant patients remains unclear. These findings support further prospective evaluation of sFLC normalization as a pragmatic blood-based marker for early risk stratification. 

Plasma Exchange in Myeloma-Associated Acute Kidney Injury: A Multicenter Propensity-Matched Cohort Study

Source

J. O'Brien, M. S. Nair, N. B. Desai, R. W. Maitta, and T. O'Brien, “Plasma Exchange in Myeloma-Associated Acute Kidney Injury: A Multicenter Propensity-Matched Cohort Study,” Journal of Clinical Apheresis 41, no. 4 (2026): e70167, https://doi.org/10.1002/jca.70167. August 5, 2026. 

Overview

Researchers performed a retrospective multicenter cohort study using the TriNetX Research Network to identify newly diagnosed multiple myeloma cases presenting between 2014 and 2024 with acute kidney failure and FLC levels > 1500 mg/L. Patients were classified by receipt of plasma exchange (PLEX) within 7 days. PLEX was not associated with improved dialysis independence or survival, supporting rapid initiation of effective anti-myeloma therapy. 

Mechanistic modeling of time-dependent antibody clearance in multiple myeloma: A physiologically based pharmacokinetic model of isatuximab

Source

Jeffrey R. Proctor, Harvey Wong, Mechanistic modeling of time-dependent antibody clearance in multiple myeloma: A physiologically based pharmacokinetic model of isatuximab, Journal of Pharmaceutical Sciences, 2026, 104455, ISSN 0022- 3549, https://doi.org/10.1016/j.xphs.2026.104455. August 5, 2026. 

Overview

Physiologically based pharmacokinetic (PBPK) models mechanistically describe antibody catabolism and FcRn recycling but have not been previously employed to characterize time-varying clearance due to changing M-protein levels. In this work, a PBPK model of antibody clearance was fitted to longitudinal M-protein and drug concentration data from multiple myeloma patients treated with isatuximab. The final model was utilized to simulate the time course of M-protein and drug exposure as a function of response, indicating an over three-fold difference in clearance between patients with no decrease in M-protein versus those with a complete therapeutic response. 

Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma?

Source

Pu■a, B., Ry■ewska, W., Handziuk, A., Tyczy■ska, A., & Kubicki, T. (2026). Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma? Expert Review of Hematology. https://doi.org/10.1080/17474086.2026.2715442 August 5, 2026. 

Overview

This review summarizes the biological rationale for targeting CD38 in SMM, including the immune-mediated and direct antimyeloma effects of daratumumab. Most patients are managed with observation, but selected high-risk patients may benefit from early intervention. The review also covers clinical evidence supporting daratumumab, particularly the phase III AQUILA trial, which showed that fixed-duration subcutaneous daratumumab delayed progression to active multiple myeloma compared with active monitoring. 

An AI-based co-registration method to improve automatic 18F-FDG uptake quantification in patients with Multiple Myeloma

Source

Bart M. de Vries, Gerben J.C. Zwezerijnen, Marijke den Hollander, M. Maqsood Yaqub, Josée Zijlstra-Baalbergen, Ronald Boellaard, An AI-based co-registration method to improve automatic 18F-FDG uptake quantification in patients with Multiple Myeloma, EANM Innovation, 2026, 100289, ISSN 3051-2913, https://doi.org/10.1016/j.eanmi.2026.100289. August 6, 2026. 

Overview

Researchers proposed an AI that generates a PET- based synthetic CT (sCT) to align the ldCT with the PET image, and we evaluated how this co-registration affects PET quantification and median-based dichotomised prognostication in patients with MM. However, misalignment between the ldCT and PET due to patient movement can impact PET quantification. Also, this study showed the feasibility of an AI- based co-registration to improve alignment between ldCT and 18F-FDG PET in patients with MM. 

Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients

Source

Kastritis, E., Filippatos, C., Gavriatopoulou, M., Theodorakakou, F., Solia, E., Ntanasis-Stathopoulos, I., Malandrakis, P., Kanellias, N., Eleutherakis- Papaiakovou, E., Migkou, M., Spiliopoulou, V., Katsadouros, I., Vlachou, A., Fotiou, D., Giannakas, K., Boutakoglou, E., Giannouli, S., Tsirigotis, P., Papanikolaou, A., Terpos, E. and Dimopoulos, M.A. (2026), Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients. HemaSphere, 10: e70435. https://doi.org/10.1002/hem3.70435 August 6, 2026. 

Overview

The International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) formulated a consensus genomic staging (CGS) of high-risk MM (HRMM), aiming to refine and homogenize the classification of high-risk disease. We evaluated the new HRMM criteria in a cohort of 1209 consecutive newly diagnosed MM patients with complete CGS data (except TP53 mutations), treated in a single center with contemporary regimens, including triplets and quadruplets, between 2010 and 2024. This validation supports its deployment in clinical practice and research to enhance the precision of risk-adapted management. 

Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study

Source

Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C Minnema, Niels van de Donk, Paula Rodriguez-Otero, Maria-Victoria Mateos, Jing Christine Ye, Chalmer Tomlinson, Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Veronique Vreys, Bonnie W Lau, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Ajai Chari; Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. Blood 2026; blood.2025031994. doi: https://doi.org/10.1182/blood.2025031994 August 6, 2026. 

Overview

Researchers report efficacy and ongoing safety from MonumenTAL-1 with 3 years of follow-up. Talquetamab is the first and only approved bispecific antibody targeting G protein-coupled receptor class C group 5 member D (GPRC5D) for treatment of relapsed/refractory multiple myeloma based on from the phase 1/2 MonumenTAL-1 study. With 3 years of follow-up, talquetamab continued to demonstrate high rates of deep and durable responses. 

Impact of severe immunoparesis degree and duration on progression-free survival in newly diagnosed multiple myeloma: a retrospective cohort study of 258 patients

Source

Tian L, Zhang Y, Chen J, Lv G, Liu X, Cui Y, Guo Y and Wu S (2026) Impact of severe immunoparesis degree and duration on progression-free survival in newly diagnosed multiple myeloma: a retrospective cohort study of 258 patients. Front. Oncol. 16:1831800. doi: 10.3389/fonc.2026.1831800 Augsut 6, 2026. 

Overview

This study aims to investigate the relationship between the degree and duration of immunoparesis at diagnosis and poor prognosis in patients with newly diagnosed multiple myeloma (NDMM). A retrospective analysis was conducted on the clinical data of 258 patients with NDMM, including the status and duration of immunoparesis and the influence of other factors on prognosis.91.5% of NDMM had varying degrees of immunoparesis. Circulating plasma cells ≥ 2% and osteolytic lesions were independent poor prognostic factors for overall survival (OS) (all P < 0.05). Immunoparesis at diagnosis and its duration are poor prognostic factors for progression-free survival (PFS)in patients with NDMM. 

IL-6-driven metabolic reprogramming of the multiple myeloma microenvironment

Source

Matamala Montoya, M., Eleveld, S., Zaal, E.A. et al. IL-6-driven metabolic reprogramming of the multiple myeloma microenvironment. Cancer Metab (2026). https://doi.org/10.1186/s40170-026-00451-4 August 6, 2026. 

Overview

Although tumor cell-intrinsic mechanisms of drug resistance are well characterized, the contribution of cells in the tumor microenvironment, particularly bone marrow stromal cells, to metabolic remodeling and therapeutic resistance remains poorly understood. Analysis of patient proteomics revealed a strong positive association between interleukin-6 abundance and expression of enzymes involved in mitochondrial metabolism, glycolysis, serine metabolism, nucleotide metabolism, and redox homeostasis. These findings identify bone marrow stromal cell-derived interleukin-6 as a central driver of tumor microenvironment-mediated metabolic reprogramming and bortezomib resistance in multiple myeloma. 

Impact of granulocyte colony- stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

Source

Wang, A.X., Shekarkhand, T., Nemirovsky, D. et al. Impact of granulocyte colony- stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01594-9 August 7, 2026. 

Overview

To assess the impact of granulocyte colony- stimulating factors (G-CSF) on risk of cytokine release syndrome (CRS), researchers included all patients with multiple myeloma who received at least one dose (step-up doses [SUD] and first treatment dose [FTD]), of commercial teclistamab, elranatamab, or talquetamab between November 2022 and April 2024 at Memorial Sloan Kettering Cancer Center (N = 186). CRS occurred in 16/22 (73%) patients with G-CSF exposure vs 76/164 (46%) of non- exposed. These findings suggest that G-CSF administration can be considered for neutropenia during bispecific antibody (BsAb) initiation. 

The HALP score is a novel prognostic biomarker in multiple myeloma: A retrospective cohort study of 450 patients

Source

Akgun Cagliyan, G., Erkurt, M. A., Yilmaz, S., Kaya, E., Coskun, E. N., Baser, M. N., Arslan, S., Ekici, A. N., Kuku, I., Karagul, H., Berber, I., Koluman, B. U., Kendir, I. C., & Hacioglu, S. (2026). The HALP score is a novel prognostic biomarker in multiple myeloma: A retrospective cohort study of 450 patients. Medicine, 105(32), e50093. https://doi.org/10.1097/MD.0000000000050093 August 7, 2026. 

Overview

This study aimed to evaluate the prognostic significance of hemoglobin, albumin, lymphocyte, and platelet (HALP) levels at diagnosis in patients with multiple myeloma (MM). We retrospectively analyzed 450 patients diagnosed with MM between 2008 and 2023. These findings suggest that the HALP score may serve as a promising complementary prognostic parameter in patients with MM. 

Treatment sequencing and emerging strategies in multiple myeloma— connecting the right nodes in the right order

Source

Podar, K. Treatment sequencing and emerging strategies in multiple myeloma— connecting the right nodes in the right order. memo (2026). https://doi.org/10.1007/s12254-026-01121-3 August 7, 2026. 

Overview

With the armamentarium continuing to expand rapidly, identifying the optimal treatment sequence from the multitude of currently available options has become a critical determinant of therapeutic success. The treatment of multiple myeloma (MM) has been (r)evolutionized by the approval of 20 new agents and more than 30 new regimens over the past two decades, with population- based data indicating that the 5-year relative survival rate now approaches 64% and emerging evidence of functional cure in at least a subset of patients. 

Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity

Source

Lad, N., Esplund, J., Grauer, D., Atrash, S., Mewawalla, P., Gadela, T., Porter, C., Mushtaq, M., Kort, J., Moore, D. C., Abdallah, A.-O., Mahmoudjafari, Z., & Snyder, J. (2026). Incidence and Associated Risk Factors in the Development of Carfilzomib-Induced Cardiovascular Toxicity. Current Oncology, 33(8), 471. https://doi.org/10.3390/curroncol33080471 August 7, 2026. 

Overview

Real-world data evaluating the incidence and risk factors are limited. Researchers conducted a multicenter retrospective cohort study of 385 adult MM patients treated with carfilzomib between January 2020 and August 2024 at three U.S. institutions. These findings support consideration of a risk- adapted cardio-oncology approach, particularly in patients with pre-existing cardiac dysfunction, where closer surveillance and early intervention may help mitigate clinically significant cardiotoxicity. 

SKY92 Identifies High-Risk Newly Diagnosed Multiple Myeloma With Inferior Progression-Free Survival and Implicates NUF2 as a Candidate Driver

Source

R. M. McAvera, I. Cymer, J. Quinn, et al., “SKY92 Identifies High-Risk Newly Diagnosed Multiple Myeloma With Inferior Progression-Free Survival and Implicates NUF2 as a Candidate Driver,” European Journal of Haematology (2026): 1–13, https://doi.org/10.1111/ejh.70282. August 7, 2026. 

Overview

This study aims to determine the prevalence and prognostic significance of the SKY92 gene-expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high-risk disease in transplant-eligible newly diagnosed multiple myeloma (TE- NDMM) patients in the Republic of Ireland. Baseline genomic risk was assessed using the MMprofiler microarray in 114 TE-NDMM patients. This first characterisation of SKY92-defined high-risk multiple myeloma in Ireland supports integrated genomic profiling for clinical risk stratification and identifies NUF2 as a promising candidate driver, demonstrating that deep profiling of high-risk disease may help to discover new targets for this challenging entity. 

Identification of Marker Immunoglobulin Rearrangements for Use by HAT-PCR in Myeloma

Source

Hughes, E., & Morley, A. (2026). Identification of Marker Immunoglobulin Rearrangements for Use by HAT-PCR in Myeloma. International Journal of Molecular Sciences, 27(16), 7128. https://doi.org/10.3390/ijms27167128 August 8, 2026. 

Overview

After sequencing and bioinformatic analysis, a marker sequence suitable for minimal residual disease analysis by HAT-PCR was obtained for 90% of the 50 samples studied. Libraries for next-generation sequencing were prepared using primers directed to framework 2, framework 3 and D, and the 6 J regions of the rearranged immunoglobulin gene from 50 diagnosed myeloma bone marrow samples. Evaluation of 24 pairs of primers showed that they were highly specific and, when used in HAT-PCR, they provided accurate quantification. 

Sparse integrative dictionary learning resolves conserved drug-response states in multiple myeloma (MM)

Source

Mingke Wu, Jin Lu, Qing Ge, Sparse integrative dictionary learning resolves conserved drug-response states in multiple myeloma (MM), Cancer Genetics, 2026, ISSN 2210- 7762, https://doi.org/10.1016/j.cancergen.2026.08.002. August 8, 2026. 

Overview

While many studies have profiled transcriptional changes before and after treatment, these responses are often analyzed within individual drugs, leaving recurrent programs across therapies insufficiently explored. Although current therapies target distinct molecular processes, many patients eventually relapse, raising the question of whether diverse treatments impose different pressures that nevertheless converge on shared transcriptional adaptation programs. We further nominated state-maintaining genes and highlighted a RFXAP-centered immune-regulatory axis that may drive the Program 8 inflammatory adaptation state and shape MM drug response. 

Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus

Source

Cavo, M., Bersanelli, M., Corso, A., Galeone, C., Mangiacavalli, S., Mina, R., Zambello, R., Antonioli, E., Belotti, A., Botta, C., Buda, G., Di Raimondo, F., Galli, M., Gay, F., Offidani, M., Petrucci, M. T., Romano, A., Zamagni, E., Semeraro, A., ... Mariani, P. (2026). Optimizing the Real-World Use of BCMA-Targeted T-Cell-Engaging Therapies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: An Italian Modified Delphi Consensus. Cancers, 18(16), 2572. https://doi.org/10.3390/cancers18162572 August 9, 2026. 

Overview

The key phases in the use of anti-BCMA bispecific antibodies (BsAbs) were identified and explored. Researchers performed a modified Delphi expert consensus study on the use of BsAbs targeting the B-Cell Maturation Antigen (BCMA) in patients with triple-class-exposed (TCE) RRMM. In this article, researchers address the main challenges related to the real-world use of anti-BCMA BsAbs in patients with TCE RRMM, offering expert recommendations to complement existing guidelines and support clinical practice. 

Monoclonal Gammopathy of Thrombotic Significance

Source

M. Ho, S. Zanwar, S. Kumar, and S. V. Rajkumar, “ Monoclonal Gammopathy of Thrombotic Significance,” American Journal of Hematology (2026): 1–16, https://doi.org/10.1002/ajh.70467. August 9, 2026. 

Overview

While development of end-organ damage in MM largely reflects increasing clonal burden, emerging evidence indicates that qualitative properties of the monoclonal immunoglobulins in MGUS can be directly pathogenic, leading to serious organ injury independent of disease burden. Along these lines, we propose monoclonal gammopathy of thrombotic significance (MGTS) as encompassing thrombotic disorders in which there is definitive, mechanistically supported evidence that a monoclonal (M)-protein associated with a clonal plasma or B-cell disorder directly contributes to thrombosis. 

Corneal Epithelial Thickness Alterations in Multiple Myeloma Patients Treated with Belantamab Mafodotin

Source

Kim, T. Y., Hong, A., Stepp, M. A., & Lee, H. (2026). Corneal Epithelial Thickness Alterations in Multiple Myeloma Patients Treated with Belantamab Mafodotin. Seminars in Ophthalmology, 1–9. https://doi.org/10.1080/08820538.2026.2711727 August 10, 2026. 

Overview

This study aims to quantify sectoral corneal epithelial thickness (CET) changes in patients with multiple myeloma treated with belantamab mafodotin using anterior segment optical coherence tomography (AS-OCT), and compare CET measurements with those of normal eyes. This retrospective observational study analyzed eight eyes from four patients with multiple myeloma who received belantamab mafodotin and subsequently discontinued therapy because of keratopathy. Sectoral AS-OCT mapping of the corneal epithelium may serve as a biomarker for quantifying belantamab mafodotin-associated ocular surface toxicity. 

Gut Microbiome Composition is Associated with Response to CD38 Antibody (Daratumumab) Treatment Among Relapsed Multiple Myeloma Patients

Source

Myo Htut, Keehoon Lee, Nitya Nathwani, Michael Rosenzweig, Murali Janakiram, Scott Goldsmith, James F Sanchez, Martha Scott, Jonathan Keats, Amrita Krishnan, Steven T Rosen, Sophia S. Wang, Gut Microbiome Composition is Associated with Response to CD38 Antibody (Daratumumab) Treatment Among Relapsed Multiple Myeloma Patients, Clinical Lymphoma Myeloma and Leukemia, 2026, ISSN 2152-2650, https://doi.org/10.1016/j.clml.2026.08.004. August 10, 2026. 

Overview

Researchers evaluated changes in the gut microbiome associated with daratumumab (dara) based therapy in 40 MM patients, before and after therapy. Growing data support interactions between host-gut microbes and treatment responses in multiple myeloma (MM), where a higher abundance of Eubacterium hallii in stool samples has been found among MM patients with negative minimal residual disease after induction therapy. The findings suggest differences in species between clinical responders and non- responders, but larger prospective studies are needed to confirm these results. 

T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis

Source

Shambhavi, S., Joy, A. A., Singh, H., Amonica, T., Grover, A., Singh, T., Paul, S. S., & Pompa, T. (2026). T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis. International Journal of Molecular Sciences, 27(16), 7179. https://doi.org/10.3390/ijms27167179 August 10, 2026. 

Overview

This meta-analysis evaluates and compares the efficacy and safety of these agents in RRMM using direct and indirect evidence. Linvoseltamab and elranatamab showed numerically longer overall survival (OS) relative to standard of care (SOC), whereas talquetamab and teclistamab showed numerically shorter OS versus SOC, within the constraints of adjusted cross-trial comparisons. 

Prospective Head-To-Head Comparison of a 10-Color Single-Tube Flow Cytometry and EuroFlow Next-Generation Flow in Multiple Myeloma Minimal Residual Disease

Source

G. E. Bae, D. J. Lim, S. H. Bang, et al., “ Prospective Head-To-Head Comparison of a 10-Color Single-Tube Flow Cytometry and EuroFlow Next-Generation Flow in Multiple Myeloma Minimal Residual Disease,” Journal of Clinical Laboratory Analysis (2026): e70332, https://doi.org/10.1002/jcla.70332. August 10, 2026. 

Overview

Minimal residual disease (MRD) assessment by next-generation flow cytometry (NGF) is an important prognostic tool in multiple myeloma (MM). Although the EuroFlow NGF assay provides highly standardized and sensitive MRD detection, its dual-tube workflow requires larger sample volumes and longer processing time, potentially limiting efficiency in routine clinical practice. The ST-10C assay demonstrated analytical performance comparable to the EuroFlow NGF assay, supporting its adoption as a more efficient and streamlined alternative for routine MRD assessment in MM. 

A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid multiple myeloma with targetable vulnerabilities

Source

Barrena, N., San José-Enériz, E., Valcárcel, L.V. et al. A myeloid-dormant metabolic transcriptome identifies a poor-prognosis subgroup in hyperdiploid multiple myeloma with targetable vulnerabilities. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01604-w August 11, 2026. 

Overview

Researchers demonstrate that transcriptomic alterations of metabolism-related genes (metabolic transcriptome) in multiple myeloma (MM), classify patients into six metabolic- transcriptional groups characterized by specific metabolic pathways and cytogenetic alterations, independent of currently described myeloma risk groups. Interestingly, hyperdiploid patients clustered into 2 groups (MM5 and MM6) with significantly distinct Progression-Free and Overall Survival. These findings highlight ACSL1 as a promising therapeutic target for MM5 and provide new insights into MM metabolic heterogeneity that may guide future precision medicine strategies. 

IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable

Source

Sarah A Bird, Marco P Licciardello, Ananya Sukhtankar, Salomon Morales, Fernando J Sialana, Yitao Xu, Amy Wilson, Harvey Che, Pradeep Ramagiri, Yakinthi Chrisochoidou, Yigen Li, Shannon Martin, Enze Liu, Brian Walker, Jyoti Choudhary, Graham Jackson, Martin Kaiser, Habib Bouguenina, Paul A Clarke, Hector Keun, Charlotte Pawlyn, IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable, Blood Neoplasia, 2026, 100281, ISSN 2950-3280, https://doi.org/10.1016/j.bneo.2026.100281. August 11, 2026. 

Overview

A major barrier to improving patient outcomes is the inevitable development of resistance to immunomodulatory (IMiD) agents. Proteomic analysis of paired patient samples, from diagnosis and relapse on IMiD, suggested similar changes in lipid pathways. 

Adipocyte-derived β-hydroxybutyrate confers metabolic resilience in multiple myeloma

Source

Song, C., Yang, P., Li, Y. et al. Adipocyte-derived β-hydroxybutyrate confers metabolic resilience in multiple myeloma. Nat Commun (2026). https://doi.org/10.1038/s41467-026-76595-0 August 11, 2026. 

Overview

Obesity is a known risk factor, but how adipocytes promote MM progression is not fully understood. Our findings position adipocyte-derived β- OHB as a critical metabolic adaptor and highlight a potential combination therapy for MM. 

PD-L1+ exosomes as biomarkers and therapeutic targets in multiple myeloma: implications for CAR-T efficacy and combination immunotherapy

Source

Xu, P., Yu, WJ., Wu, SH. et al. PD-L1+ exosomes as biomarkers and therapeutic targets in multiple myeloma: implications for CAR-T efficacy and combination immunotherapy. Biomark Res (2026). https://doi.org/10.1186/s40364-026-00980-6 August 11, 2026. 

Overview

Associations with clinicopathological features, treatment response, and progression-free survival (PFS) were analyzed. A total of 89 patients with MM were enrolled, including 34 patients with RRMM treated with CAR-T therapy. PD-L1+ exosome levels in PB and BM were significantly elevated in newly diagnosed MM and RRMM compared with healthy controls, and were closely associated with adverse prognostic features, including high tumor burden, extramedullary lesions, and high-risk cytogenetic features, whereas plasma sPD-L1 showed no significant clinical correlations. 

Spinal-Multiple-Myeloma-SEG: Segmentation of spinal multiple myeloma lesions in dual-energy CT

Source

Nohel, M., Valek, V., Rohan, T. et al. Spinal-Multiple-Myeloma-SEG: Segmentation of spinal multiple myeloma lesions in dual-energy CT. Sci Data (2026). https://doi.org/10.1038/s41597-026-08061-x August 11, 2026. 

Overview

Researchers present a unique dataset comprising dual-energy low-dose CT scans from 67 patients diagnosed with multiple myeloma, with a total of 72 scans. It addresses the current lack of publicly available datasets focused on dual-energy CT–based lesion segmentation in patients with multiple myeloma (acquired using dual-layer CT technology, Philips IQon Spectral CT), and may support the development and validation of algorithms for lesion detection, disease monitoring, and assessment of treatment response. 

Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye

Source

Bozdemir, A., Hacıoğlu, S., Akgün Çağlıyan, G., Alayvaz Aslan, N., Uzun, S. U., Kara, K., Iltar, U., Yücel, O. K., Ataş, Ü., Arslan Kirezli, S., Gemici, A. İ., Alacacıoğlu, İ., Yeniay, M. K., Bilgir, O., Narlı Özdemir, Z., Haydaroğlu Şahin, H., Uysal, A., Aksöz, Z., Güven, Z. T., ... Güler, N. (2026). Elranatamab in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Study from Türkiye. Journal of Clinical Medicine, 15(16), 6232. https://doi.org/10.3390/jcm15166232&nbsp;

Overview

Researchers evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed/refractory multiple myeloma (RRMM). This study represents one of the first multicenter real-world evaluations of elranatamab in Türkiye. Infectious complications, including CMV events, remained clinically relevant, emphasizing the importance of supportive care. 

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

Source

Gundesen MT, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Madsen JS, et al. Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers. Br J Haematol. 2026; 00: 1–9. https://doi.org/10.1111/bjh.70612 August 11, 2026. 

Overview

This follow-up study investigated the effects of ZOL in patients achieving very good partial response (VGPR) compared to patients who did not and whether bone turnover markers could identify patients at an increased risk of progressive bone disease (PBD) following treatment cessation. The Magnolia study demonstrated that continuation of zoledronic acid (ZOL) beyond 2 years reduces the risk of progressive bone disease (PBD) in patients with multiple myeloma (MM). 

USP8 controls proteostasis pathways in B cells and multiple myeloma

Source

Dufner, A., Thery, F., Monaco, G. et al. USP8 controls proteostasis pathways in B cells and multiple myeloma. Leukemia (2026). https://doi.org/10.1038/s41375-026- 03086-y August 11, 2026. 

Overview

USP8 represents a vulnerability gene in multiple myeloma (MM), suggesting a functional role in the B- and plasma cell compartment. Here, researchers analyzed mice with stage-specific Usp8 deletion during B-cell development and investigated its role in patient-derived MM cells that are sensitive or resistant to the proteasome inhibitor Bortezomib (BTZ) using USP8 depletion and treatment with DUB-IN-2, a reported USP8 inhibitor. Thus, these findings highlight the therapeutic potential of targeting USP8 and identify the combination of DUB-IN-2 and BTZ as a novel strategy for treating BTZ-resistant MM. 

Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma

Source

Brooks, C., Mader, L., Kennedy, K. et al. Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma. Exp Hematol Oncol 15, 77 (2026). https://doi.org/10.1186/s40164-026-00816- x August 12, 2026. 

Overview

While current prescribing information for Tec and Tal recommend repeat step-up dosing (SUD) for prolonged dose delays, we report a series of six patients (pts) who continued therapy with extended dosing intervals (EDI) (8–12 weeks) without repeating SUD. At the time of this report, all patients in this cohort have sustained, deep disease response and remain on bispecific antiobdy (BsAb) therapy. Despite small sample size, this report adds to limited available data supporting safe and feasible omission of SUD in RRMM pts slated for Tec/Tal therapy resumption via EDI. 

Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity

Source

Wiedmeier-Nutor, J., Riggs, D., Stein, C. et al. Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026- 01597-6 August 12, 2026. 

Overview

Multiple myeloma (MM) is an incurable plasma cell neoplasm characterized by diverse and complex genetic abnormalities, including translocations of immunoglobulin (Ig) genes and a hyperdiploid karyotype. In this study, researchers conducted an integrated multi-omics analysis in five hyperdiploid cell lines established from serial samples from a single relapsed/refractory hyperdiploid MM patient, enabling detailed characterization of the genetic landscape and molecular alterations through disease progression. 

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy

Source

Zolotov, E., Mody, R., Doucette, K., Chappell, A., Accolatse-Mati, C., Parmar, H., Di Palma-Grisi, J., Biran, N., Phull, P., Franz, J., Siegel, D. S., & Vesole, D. H. (2026). Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy. Current Oncology, 33(8), 475. https://doi.org/10.3390/curroncol33080475 August 12, 2026. 

Overview

Researchers conducted a multicenter retrospective analysis of all MM patients who received CAR-T therapy while on hemodialysis (HD) at two U.S. centers between June 2021 and December 2025. Multiple myeloma (MM) patients with end-stage renal disease (ESRD) requiring hemodialysis (HD), who are disproportionately Black, have been excluded from all pivotal trials of BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy, leaving a critical evidence gap in this population. CAR-T therapy is feasible, relatively safe, and effective in carefully selected HD-dependent MM patients, supporting expanded eligibility with appropriate dose modification. 

Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease

Source

Dian Zhou, Yuekun Qi, Sha Ma, Qian Sun, Weiying Gu, Jieyun Xia, Xiaotian Zhang, Wei Chen, Hai Cheng, Kunming Qi, Feng Zhu, Fan Xia, Lili Zhu, Hujun Li, Huanxin Zhang, Dongmei Yan, Tingting Qiu, Yanlei Zhang, Shuixiu Peng, Wei Sang, Depeng Li, Alex H. Chang, Bin Pan, Zhiling Yan; Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease. Blood 2026; 148 (7): 831–840. doi: https://doi.org/10.1182/blood.2026033506 August 13, 2026. 

Overview

Researchers developed anti–B-cell maturation antigen (anti-BCMA)/G protein–coupled receptor, class C group 5 member D (GPRC5D) bispecific chimeric antigen receptors (CARs) to investigate the activity and safety of the CAR T cells in patients with extraosseous EMD. Patients with relapsed or refractory multiple myeloma (RRMM) with extraosseous extramedullary disease (EMD) have inferior outcomes and lack effective therapies. These findings support that anti- BCMA/GPRC5D bispecific CAR T cells induced a high response rate in patients with RRMM with extraosseous EMD, and the safety profile was manageable. 

Macrophage migration inhibitory factor promotes immune evasion in multiple myeloma through myeloid-derived suppressor cell immunosuppression and major histocompatibility complex class I downregulation: implications for targeted therapy

Source

Wen J, Huang J, Xu J, Zhao P, Zhao X, He S, Li L, Liu X, Luo H, Mi Z, Zhang Y, Gao Q, Yang H, Feng Y, Zhai X, Wang F, Zhang D, Zhang L, Tang W, Bi E, Niu T, Zheng Y. Macrophage migration inhibitory factor promotes immune evasion in multiple myeloma through myeloid-derived suppressor cell immunosuppression and major histocompatibility complex class I downregulation: implications for targeted therapy. Haematologica; https://doi.org/10.3324/haematol.2026.300778 [Early view]. August 13, 2026. 

Overview

In MM cells, MIF suppresses the COPS5/STAT1/NLRC5 signaling axis, resulting in downregulation of the major histocompatibility complex class I (MHC-I) antigen presentation pathway and reduced T cell-mediated cytotoxicity against MM cells. Therapeutically, combined treatment with the MIF inhibitor 4-IPP and dexamethasone delayed MM progression and prolonged survival in a mouse MM model. These findings reveal MIF as a critical mediator of immune escape in MM and highlight the therapeutic potential of MIF-targeted strategies for MM treatment. 

CDK4/6i Reverses MEIS2 Inhibition of CRL4CRBN and Promotes BCMA Loss to Enhance IMiD/CELMoD Therapy in Multiple Myeloma

Source

Xiangao Huang, David Jayabalan, Maurizio Di Liberto, Zhengming Chen, Scott A. Ely, Tomer M. Mark, Gang Lin, Ruben Niesvizky, Selina Chen-Kiang, CDK4/6i Reverses MEIS2 Inhibition of CRL4CRBN and Promotes BCMA Loss to Enhance IMiD/CELMoD Therapy in Multiple Myeloma, Blood Neoplasia, 2026, 100285, ISSN 2950-3280, https://doi.org/10.1016/j.bneo.2026.100285. August 13, 2026. 

Overview

MEIS2 was identified biochemically as a substrate of cereblon (CRBN), a receptor of the CRL4CRBN E3 ubiquitin ligase required for the anti-myeloma activity of immunomodulatory drugs (IMiD)s and the second generation cereblon E3 ligase modulatory drug (CELMoD). Researchers discovered that MEIS2 is aberrantly expressed in bone marrow myeloma cells (BMMC)s, and that high MEIS2, CDK4 or CDK6 and low CRBN expression predisposes patients to inferior progression-free survival in IMiD therapy. Thus, inhibition of CDK4/6 reverses MEIS2 inhibition of CRL4CRBN in cooperation with IMiD and CELMoD, and mitigates MEIS2-mediated BCMA signaling for survival, suggesting targeting MEIS2 or CELMoD and CDK4/6 as a new strategy to advance immunomodulatory drug therapy for multiple myeloma. 

Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Patients

Source

Lee M, Min CK, Yhim HY, Yoon DH, Lee SM, Shin HJ, Jo JC, Jung J, Kim Y, Lee JH, Lee JH, Kim S, Jung SH, Kim K. Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Patients. Cancer Res Treat. 2026 Aug 13. doi: 10.4143/crt.2026.0585. Epub ahead of print. 

Overview

Researchers compared outcomes between ASCT and non-ASCT approaches in newly diagnosed DDMM. The role of autologous stem cell transplantation (ASCT) in transplant-eligible patients with dialysis-dependent multiple myeloma (DDMM) remains unclear. After accounting for immortal time bias, the apparent survival advantage was attenuated and should be regarded as hypothesis-generating, warranting confirmation in prospective studies. 

Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study

Source

Touzeau, C., Perrot, A., Hulin, C. et al. Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study. Leukemia (2026). https://doi.org/10.1038/s41375-026-03094-y August 13, 2026. 

Overview

Although outcomes of patients with biomarker-defined newly diagnosed MM (NDMM) are now better characterized, prospective studies specifically addressing the prognosis of these patients are needed [2]. The CASSIOPEIA trial led to the approval of daratumumab combined with VTD for the treatment of transplant-eligible (TE) NDMM [3, 4]. Univariate comparisons between groups were performed using the χ2 and Fisher exact test for categorical variables, the Mann-Whitney U test for continuous variables and the log-rank test for survival outcomes (PFS and OS). 

Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers

Source

Ponnusamy, K., Karaxhuku, K., Jiang, Y. et al. Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers. Nat Commun (2026). https://doi.org/10.1038/s41467-026-76718-7 August 14, 2026. 

Overview

This study aims to maximize the anti-cancer activity of CAR-iNKT against the blood cancer multiple myeloma, researchers investigated optimal CAR designs and their combination with new iNKT- specific engagers. Thus, optimised iNKT-based, dual-target, dual-modality immunotherapy has enhanced anti-tumor activity against multiple myeloma and potentially other malignancies. 

Dynamic Inflammatory and Erythrocyte-Derived Biomarkers in Newly Diagnosed Multiple Myeloma: A Longitudinal Analysis of Classical and Novel Indices

Source

Stroe-Ionescu, A.-Ş., Boldeanu, L., Pǎtraşcu, A. M., Goanțǎ, J.-G., Siloși, I., Assani, M.-Z., Rotaru, I., Tǎnase, A. D., & Boldeanu, M. V. (2026). Dynamic Inflammatory and Erythrocyte-Derived Biomarkers in Newly Diagnosed Multiple Myeloma: A Longitudinal Analysis of Classical and Novel Indices. Biomedicines, 14(8), 1839. https://doi.org/10.3390/biomedicines14081839

Overview

Inflammatory and hematologic indices derived from routine blood tests have been increasingly investigated as prognostic biomarkers in multiple myeloma (MM). We conducted a retrospective study including 122 patients with newly diagnosed MM. These findings support integrating longitudinal biomarker assessment into future risk stratification models for MM. 

Multiple myeloma and therapy reshape the bone marrow niche to durably constrain immune reconstitution and vaccine responsiveness

Source

Aishwarya Chander, Samir Rachid Zaim, Medbh A. Dillon, Palak C. Genge, Nicholas Moss, Patrick I. McGrath, Mackenzie S. Kopp, Kevin J. Lee, Emma L. Kuan, Julian Reading, Veronica Hernandez, Xiaoling Song, Mansi Singh, Jessica Garber, Christian M. LaFrance, Garth L. Kong, Marla C. Glass, Eden Leigh W. Davis, David Glass, Yudong D. He, Alexander T. Heubeck, Erin K. Kawelo, Upaasana Krishnan, Cara Lord, Paul Meijer, Regina R. Mettey, Blessing Musgrove, Lauren Y. Okada, Vaishnavi Parthasarathy, Tao Peng, Cole G. Phalen, Stanley R. Riddell, Charles R. Roll, Tyanna J. Stuckey, Elliott G. Swanson, Zach J. Thomson, Morgan D.A. Weiss, Peter J. Wittig, Stephanie D. Anover-Sombke, Ernest M. Coffey, Lynne A. Becker, Thomas F. Bumol, Ananda W. Goldrath, Evan W. Newell, Philip D. Greenberg, Xiao-jun Li, Susan M. Kaech, Peter J. Skene, Lucas T. Graybuck, Love Tätting, Mikael Sigvardsson, Mary Kwok, Damian J. Green, Troy R. Torgerson, Melinda L. Angus-Hill, Multiple myeloma and therapy reshape the bone marrow niche to durably constrain immune reconstitution and vaccine responsiveness, Cell Press Blue, 2026, 100087, ISSN 3051-3839, https://doi.org/10.1016/j.cpblue.2026.100087. August 14, 2026. 

Overview

Researchers found that the tumor imposes a compartment-specific immune program where the marrow exhibits metabolic and inflammatory changes that bias hematopoiesis and alter cytotoxic effector programs not mirrored in the blood. Infections are the most common cause of non-relapse mortality in multiple myeloma (MM), but the basis of persistent immune dysfunction is obscured by patient heterogeneity and complex treatment regimens, including autologous stem cell transplant (ASCT). Together, these findings define how myeloma and its treatment durably reshape immunity from the marrow outward. 

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

Source

Faruq O, Iyer D, Wang P, Shrestha M, Wei C, Schimmer AD, et al. CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib. Br J Haematol. 2026; 00: 1–10. https://doi.org/10.1111/bjh.70736 August 14, 2026. 

Overview

Transcriptomic analysis of patient datasets revealed that high CD47 expression was associated with enrichment of the JAK–STAT3 and MYC pathways, and CD47 levels positively correlated with STAT3 and MYC expression, suggesting a potential regulatory interplay among these molecules. Moreover, Rux synergized with bortezomib in myeloma cell lines and primary patient samples but spared normal cells. Collectively, these findings identify CD47 as an oncogenic driver with an intrinsic signalling function in MM and highlight the CD47– STAT3–MYC axis as a promising therapeutic target. 

Preexisting cardiovascular disease and inpatient arrhythmias after autologous stem cell transplantation for multiple myeloma: a National Inpatient Sample analysis

Source

Garcia Pleitez, H., Guevara Rodriguez, N., Puchongmart, C., Soliman, D., Ortiz Maldonado, A., Coreas, N., … Kunwor, R. (2026). Preexisting cardiovascular disease and inpatient arrhythmias after autologous stem cell transplantation for multiple myeloma: a National Inpatient Sample analysis. Baylor University Medical Center Proceedings, 1–4. https://doi.org/10.1080/08998280.2026.2716565 August 14, 2026. 

Overview

Researchers evaluated present-on-admission (POA)–coded new-onset inpatient arrhythmias according to preexisting CVD status. Autologous stem cell transplantation (ASCT) remains the standard for transplant-eligible multiple myeloma (MM) patients. These findings are hypothesis-generating and warrant validation in larger clinically adjudicated cohorts. 

Patterns and perceptions of supplement use among patients with plasma cell disorders

Source

Malik, M.A., Schach, E., Leyfman, Y. et al. Patterns and perceptions of supplement use among patients with plasma cell disorders. Blood Cancer J. 16, 137 (2026). https://doi.org/10.1038/s41408-026-01603-x August 14, 2026. 

Overview

Despite widespread use, 59% of oncologists report having limited education on supplements, which is a barrier to effectively counsel patients and a missed opportunity to strengthen patient-provider trust. As novel treatments have improved survival in patients with plasma cell disorders (PCDs), there is a growing interest in complementary medicine (CM), particularly dietary supplements (vitamins, minerals, antioxidants, and herbs), amongst patients with cancer. Common sources to receive information about supplements included a hematologist/oncologist (46%), online medical resources (46%), primary care provider (36%), myeloma education websites (28%), and online patient support forums (20%). 

Development and multicenter validation of a predictive nomogram for infection risk in patients with multiple myeloma

Source

Chen, S., Chen, Z., Chen, H. et al. Development and multicenter validation of a predictive nomogram for infection risk in patients with multiple myeloma. Ann Hematol (2026). https://doi.org/10.1007/s00277-026-07228-1 August 15, 2026. 

Overview

This study aims to explore the key influencing factors of the risk of nosocomial infection in patients with multiple myeloma (MM), to construct a prediction model to effectively assess the risk of infection, and to provide a basis for individualized infection prevention and control. The prediction model integrating ISS staging, HGB, ALB, CRP, Monoclonal Protein content, PCT, and UA has excellent discriminatory and calibration abilities, and may provide a reliable tool for risk stratification of infection in MM patients. 

A Concise Alternative Process to Melphalan Flufenamide Hydrochloride

Source

Patil, S.R., Patil, P.N., Urunkar, G. et al. A Concise Alternative Process to Melphalan Flufenamide Hydrochloride. J Pharm Innov 22, 74 (2027). https://doi.org/10.1007/s12247-026-10902-6 August 15, 2026. 

Overview

This article presents a new three-step process for Melphalan flufenamide (Melflufen) hydrochloride, a clinically significant peptide–drug conjugate used for the treatment of multiple myeloma. Using this methodology, pharmaceutical-grade Melflufen hydrochloride was obtained with a high purity of 99.7% as determined by HPLC, highlighting the robustness and industrial applicability of the process. 

The Transformation of the Microenvironment: From Observer to Coordinator in Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma Development

Source

A. A. M. A. El-Sehrawy, A. J. Shnoudeh, I. Yuldashev, et al., “ The Transformation of the Microenvironment: From Observer to Coordinator in Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma Development,” Hematological Oncology (2026): e70240, https://doi.org/10.1002/hon.70240. August 15, 2026. 

Overview

Although progression is partly shaped by intrinsic genetic and epigenetic changes within the plasma cell clone, increasing evidence indicates that the bone marrow microenvironment plays a decisive role in determining whether the clone remains clinically silent or evolves toward symptomatic disease. Understanding this coordinated microenvironmental remodeling may improve risk stratification and support therapeutic strategies that target both the plasma cell clone and its supportive niche. 

Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia

Source

Gration, B., Wellard, C., Moore, E. et al. Impact of socioeconomic status on treatment and survival in multiple myeloma in Australia. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01596-7 August 15, 2026. 

Overview

Researchers assessed the impact of non-biological social determinants of health on treatment and survival outcomes in Australia using data from the Australian and New Zealand Myeloma and Related Diseases Registry. A total of 4405 patients diagnosed with MM between June 2012 and October 2025 across 44 Australian sites were assigned an area-level socioeconomic status (SES) using individual postcodes. This suggests that non-biological factors continue to influence access to standard-of-care therapy and survival, warranting further research to identify and address barriers to equitable care. 

2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group

Source

Beksac M, Mastanzade M, Degirmenci B et. al. 2026 Myeloma Treatment Guidelines of the Turkish Myeloma Study Group
Clinical Lymphoma, Myeloma and Leukemia, 2026; 0

Overview

The treatment landscape of multiple myeloma (MM) is evolving rapidly, driven by the approval of new therapies and the increasing integration of advanced response- assessment tools, including measurable residual disease (MRD). This effort aims to support new drug approvals and facilitate the implementation of diagnostic and response-assessment tools in routine clinical practice in Türkiye. 

A dual green chromatographic platform for bioanalytical quantification and pharmacokinetic characterization of the BBD antineoplastic regimen

Source

Marco M.Z. Sharkawi, Noha H. Amin, Norhan R. Mohamed, Loah R. Hemeda, Shimaa S. Zaki, A dual green chromatographic platform for bioanalytical quantification and pharmacokinetic characterization of the BBD antineoplastic regimen, Analytica Chimica Acta, Volume 1411, 2026, 345652, ISSN 0003-2670, https://doi.org/10.1016/j.aca.2026.345652. August 15, 2026. 

Overview

The BBD salvage regimen, consisting of bendamustine (BEN), bortezomib (BOR), and dexamethasone (DEX), has demonstrated efficacy in patients with relapsed or refractory MM. However, no analysis has been reported for the simultaneous determination of this regimen, and potential pharmacokinetic interactions among its components remain insufficiently explored. The revealed measurable changes in pharmacokinetic parameters suggest potential pharmacokinetic interactions among the components of the BBD regimen. 

Pre-Transplant Endothelial Activation and Stress Index (EASIX) and Albumin-Modified mEASIX (mEASIX_alb) Predict Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Source

Güllü Koca, T., Koca, N., Hunutlu, F. Ç., Çubukçu, S., Yılmaz, R., Ersal, T., Gürsoy, V., Pınar, I. E., Özkocaman, V., & Özkalemkaş, F. (2026). Pre-Transplant Endothelial Activation and Stress Index (EASIX) and Albumin-Modified mEASIX (mEASIX_alb) Predict Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Medicina, 62(8), 1572. https://doi.org/10.3390/medicina62081572

Overview

Endothelial dysfunction is increasingly recognized as a key determinant of transplant outcomes. Researchers evaluated the pre-transplant prognostic value of EASIX, an albumin-modified formulation (mEASIX_alb), and nutritional indices (Prognostic Nutritional Index [PNI] and Controlling Nutritional Status [CONUT] score) in a large MM-ASCT cohort. EASIX retained prognostic significance across transplant eras and in a cytogenetically characterized subset, supporting its era-independent and cytogenetics-independent utility. 

Prognostic Significance of Peripheral Blood Neutrophil- To-Lymphocyte Ratio (NLR), Monocyte-To-Lymphocyte Ratio (MLR), and Platelet-To- Lymphocyte Ratio (PLR) in Patients With Multiple Myeloma: A Retrospective Cohort Study

Source

L. Zhang, B. Ma, and J. Zhang, “Prognostic Significance of Peripheral Blood Neutrophil- To-Lymphocyte Ratio (NLR), Monocyte-To-Lymphocyte Ratio (MLR), and Platelet-To- Lymphocyte Ratio (PLR) in Patients With Multiple Myeloma: A Retrospective Cohort Study,” Journal of Clinical Laboratory Analysis (2026): e70308, https://doi.org/10.1002/jcla.70308. August 17, 2026. 

Overview

Researchers investigated whether simple systemic inflammation markers—neutrophil-to-lymphocyte ratio, monocyte-to- lymphocyte ratio, and platelet-to-lymphocyte ratio—could improve prognostic assessment and identify high-risk patients among newly diagnosed MM patients treated with novel agents in a retrospective cohort. They conducted a single-center retrospective analysis of 268 newly diagnosed MM patients between January 2019 and December 2023. Kaplan–Meier analysis showed that patients with high NLR and MLR had significantly inferior OS and PFS. 

Pathogenesis and Translational Perspectives in Myeloma- Associated Nephropathy

Source

Sanders, P. W. (2026). Pathogenesis and Translational Perspectives in Myeloma- Associated Nephropathy. Journal of the American Society of Nephrology https://doi.org/10.1681/ASN.0000001249 August 17, 2026. 

Overview

Important predisposing factors include the physicochemical characteristics and the amount of the FLC present in the tubular nephron. This narrative review integrates obstructive cast formation and proximal tubulopathy to consider a unified translational therapeutic approach for myeloma kidney to improve outcomes in this devastating complication of multiple myeloma. 

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results

Source

Thomas Dejoie, Neila Rebouh, Jill Corre, Soraya Wuilleme, Françoise Kraeber- Bodere, Cyrille Hulin, Aurore Perrot, Cyrille Touzeau, Xavier P. Leleu, Bertrand Arnulf, Lionel Karlin, Philippe Moreau, Helene Caillon; Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results. Blood 2026; blood.2026033773. doi: https://doi.org/10.1182/blood.2026033773 August 17, 2026. 

Overview

Minimal residual disease (MRD) status is widely used to assess depth of response and predict outcome in multiple myeloma, but bone marrow MRD testing is invasive and subject to sampling variability. Blood-based mass spectrometry (MS), which measures patient-specific monoclonal immunoglobulins, offers a non-invasive approach to monitoring residual disease. These findings support a complementary, phase-adapted role for serum MS alongside bone marrow MRD testing, enabling frequent non-invasive monitoring during maintenance while preserving bone marrow assessment when maximum sensitivity is required. 

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy

Source

Barilà G, Grassi A, Ruocco V, Liberatore C, Olivari E, Tinelli M, et al. Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy. Br J Haematol. 2026; 00: 1–11. https://doi.org/10.1111/bjh.70751 August 18, 2026. 

Overview

This real-life study aims to evaluate the effectiveness of the regimens licensed in Italy and used in a cohort of patients who relapsed during Len maintenance after AHSCT. The extensive use of lenalidomide (Len) in the first-line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len-R) at first relapse. Our data in a homogeneous cohort of Len-R patients treated at first relapse demonstrated that the anti-CD38 MoAb-based combinations, particularly Isa-KD, represented the standard of care before the approval of anti-B cell maturation antigen (BCMA) immunotherapy. 

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

Source

Zweegman, S., Usmani, S.Z., Hungria, V. et al. Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS. Leukemia (2026). https://doi.org/10.1038/s41375-026-03111-0 August 18, 2026. 

Overview

The International Myeloma Working Group (IMWG) frailty index, recommended by the IMWG and the European Myeloma Network, incorporates age, comorbidities, and functional status via patient-reported assessments, i.e., the Katz Index of Independence in Activities of Daily Living (ADL) and the Lawton Instrumental Activities of Daily Living (IADL). Daratumumab, lenalidomide, and dexamethasone (DRd) is approved to treat transplant- ineligible patients with newly diagnosed multiple myeloma (NDMM) based on the phase 3 MAIA trial [1,2,3]. These findings, along with known DRd benefits in frailty subgroups [11, 12], help to inform daratumumab selection in patients with NDMM who do not receive frontline transplant, with the ability to tailor the regimen based on patient fitness, bortezomib eligibility, treatment goals, and treatment access. 

Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma

Source

Venglar, O., Radova, E., Warmuzova, M., Bilek, D., Kudelkova, M., Jasinkova, K., Muronova, L., Broskevicova, L., Kapustova, V., Vrana, J., Novakova, T., Karasova, K., Hornakova, M., Popkova, T., Mihalyova, J., Plonkova, H., Simicek, M., Radocha, J., Sevcikova, T., Zihala, D., Bago, J., Hajek, R. and Jelinek, T. (2026), Anti-BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma. HemaSphere, 10: e70455. https://doi.org/10.1002/hem3.70455 August 18, 2026. 

Overview

Among the primary immune components engaged in antiviral defense, dendritic cells (DCs) serve as essential co-activators and professional antigen-presenting cells (APCs). Overall, 388 unique samples from 72 MM patients were assessed in this study in multiple cohorts (Table S1). These findings also highlight the potential of BCMA-targeted therapy in blastic pDC neoplasm.21 Furthermore, in vitro functional assays demonstrated a reduced capacity to produce IFN-α in MM patients receiving anti-BCMA therapy compared with anti-GPRC5D therapy, suggesting a potential reduction in antiviral immune responses. 

Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management

Source

S. V. Rajkumar, “ Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management,” American Journal of Hematology (2026): 1–24, https://doi.org/10.1002/ajh.70475. August 18, 2026. 

Overview

Risk Stratification: High-risk multiple myeloma is defined by the presence of del(17p), p53 mutation, or bi- allelic del(1p); t(4;14), t(14;16), t(14;20) in combination with gain(1q) or del(1p); or gain(1q) plus del(1p). Initial Therapy: Initial therapy consists of a quadruplet regimen consisting of anti-CD38 monoclonal antibody (daratumumab or isatuximab) plus bortezomib, lenalidomide, dexamethasone (VRd) followed by autologous stem cell transplantation in eligible patients. Management of Smoldering Multiple Myeloma: Daratumumab for 3 years should be considered in high-risk smoldering multiple myeloma. 

Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool

Source

Kevin Charles Miller, Teng Fei, Ruben J. Faustino Ramos, Francesca Castro, Ana Gradissimo, Torin Block, Issam Hamadeh, Kylee H. Maclachlan, Malin L. Hultcrantz, Hani Hassoun, Sham Mailankody, Sridevi Rajeeve, Francesco Maura, Maximilian Merz, Hamza Hashmi, Ross Firestone, Eric Jurgens, Gunjan L. Shah, Michael Scordo, Heather J. Landau, Sergio A. Giralt, Neha Korde, Matthew J. Pianko, Saad Z. Usmani, Jonathan U. Peled, Urvi A. Shah, Alexander M. Lesokhin; Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool. Clin Cancer Res 2026; https://doi.org/10.1158/1078-0432.CCR-26-0752 Augsut 18, 2026. 

Overview

As the gut microbiota shapes BA metabolism, we evaluated whether perturbations of the microbiota and bile acid (BA) pool are associated with lenalidomide-related diarrhea (LRD). Lenalidomide is integral to multiple myeloma therapy, but long-term use is frequently complicated by diarrhea, which diminishes patient quality of life. These findings implicate impaired microbial BA metabolism as a contributor to LRD and support investigating microbiota-targeted strategies to mitigate this toxicity. 

Beauvericin Exerts Antitumor Effects on Multiple Myeloma by Disrupting the USP9X-Bcl-2 Interaction to Promote Bcl-2 Degradation

Source

Rui Jin, Runfeng Ni, Ning Ding, Yuchen Tao, Shuyang Cai, Yirong Shi, Milin Liu, Yirong Chen, Letian Yu, Jiahui Lu. Beauvericin Exerts Antitumor Effects on Multiple Myeloma by Disrupting the USP9X-Bcl-2 Interaction to Promote Bcl-2 Degradation. Front. Biosci. (Landmark Ed) 2026, 31(8), 51975. https://doi.org/10.31083/FBL51975 (registering DOI) August 18, 2026. 

Overview

This study aimed to elucidate the mechanism of beauvericin in MM. This study utilized the mouse Sp2/0 cell line, the human U266 cell line, and a subcutaneous tumor allograft model in C57BL/6J mice. In vivo studies demonstrated that beauvericin treatment suppressed the growth of subcutaneous MM tumors C57BL/6J mice. 

Carrier-Free Berberine/Nitidine Chloride Self-Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma

Source

Y. Lv, S. Liu, H. Wu, et al. “Carrier-Free Berberine/Nitidine Chloride Self-Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma.” Advanced Science (2026): e77174. https://doi.org/10.1002/advs.77174 August 18, 2026. 

Overview

Driven by cooperative π-π stacking and van der Waals forces, BBR/NC-SAPs display superior anti-MM efficacy and optimized biosafety as compared to the free-drug combination. Quantitative proteomics and functional landscapes showed that BBR/NC- SAPs robustly activate iron-dependent ferroptosis, as evidenced by massive lipid peroxidation, intracellular Fe2+ overload, and mitochondrial depolarization. 

BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians

Source

Banerjee, R., Hashmi, H., Chaudhary, P.M. et al. BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians. Adv Ther (2026). https://doi.org/10.1007/s12325-026-03737-7 August 19, 2026. 

Overview

Researchers aimed to achieve consensus on optimal bridging therapy (BT) selection for patients with relapsed/refractory multiple myeloma (RRMM) undergoing chimeric antigen receptor T-cell (CAR-T) therapy. Panelists (N = 15; all managing –60–100 patients with RRMM within the past year; > 5 years of practice: 86.7%) reached consensus on key attributes influencing bridging therapy (BT) selection (disease burden, aggressive disease, performance status, comorbidities, line of therapy, age, frailty). This study synthesized expert physician perspectives to develop a consensus-based framework to optimize BT selection, linking five key patient attributes to clinical objectives, with goals extending beyond disease stabilization to enhancing CAR-T efficacy and safety. 

The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022

Source

Comerford, C., Hayden, P.J., Eikema, D.-J., Koster, L., Sauer, S., Broers, A., Rabin, N., Bastie, J.N., Gedde-Dahl, T., Giaccone, L., Richardson, D., Carlson, K., Besemer, B., de Colella, J.-M.S., Zeiser, R., Vincent, L., Pabst, T., Cairoli, A., Schuermans, C., Poiani, M., Raj, K., Drozd-Sokolowska, J., Garderet, L., Najjar, I.E., Beksac, M. and McLornan, D.P. (2026), The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022. Br J Haematol. https://doi.org/10.1111/bjh.70759 August 19, 2026. 

Overview

Given the increasing importance placed on developing personalized therapeutic approaches, further understanding of the impact of these high- risk cytogenetic lesions on survival is needed. Researchers therefore sought to characterize outcomes in a large cohort of patients with del(17p) MM. In conclusion, this large registry study highlights that AHSCT-eligible patients with MM and del(17p) continue to have poorer outcomes with standard approaches to therapy and that patients with t(4;14) and del(17p) (two high-risk cytogenetic abnormalities) represent an ultra-high-risk cohort. 

Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma

Source

Dreyfuss, A.D., Yahalom, J., Rajeeve, S. et al. Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma. Blood Cancer J. 16, 139 (2026). https://doi.org/10.1038/s41408-026-01607-7 August 19, 2026. 

Overview

Serologic markers and marrow-based minimal residual disease are used to monitor for progression and assess systemic disease burden, but they do not capture the anatomic distribution or lesion-level heterogeneity of resistant disease. B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy produces high response rates and durable remissions in relapsed/refractory multiple myeloma (RRMM), yet most patients ultimately relapse. Pre-LDC radiologic disease burden and EM/PM involvement, together with persistent day 30 metabolic activity, identify high-risk patients and lesions, supporting the use of risk-adapted strategies to improve the durability of cellular therapy. 

Risk factors for carfilzomib-related cardiovascular adverse events in Chinese patients with multiple myeloma: A real-world retrospective cohort study

Source

Wei X-C, Chen F, Xiao Y, Lyu H-R. Risk factors for carfilzomib-related cardiovascular adverse events in Chinese patients with multiple myeloma: A real-world retrospective cohort study. Journal of International Medical Research. 2026;54(8). doi:10.1177/03000605261476840 August 20, 2026. 

Overview

This study aimed to evaluate the incidence of and identify the risk factors for cardiovascular adverse events associated with carfilzomib in Chinese patients with multiple myeloma in a real-world setting. Researchers conducted a real-world retrospective cohort study of cardiovascular adverse events in patients with multiple myeloma treated with carfilzomib at Tianjin First Central Hospital between August 2022 and April 2026. Patients at high risk, particularly those with elevated baseline N-terminal pro-B-type natriuretic peptide levels, may therefore require close cardiovascular monitoring throughout the course of carfilzomib treatment. 

Venous thromboembolism prophylaxis in multiple myeloma patients receiving immunomodulatory therapy: a systematic review and meta-analysis

Source

Tippins, M., Loader, A., Al-Lami, B. et al. Venous thromboembolism prophylaxis in multiple myeloma patients receiving immunomodulatory therapy: a systematic review and meta-analysis. J Thromb Thrombolysis (2026). https://doi.org/10.1007/s11239- 026-03380-7 August 20, 2026. 

Overview

Patients with multiple myeloma receiving immunomodulatory drugs have an increased risk of venous thromboembolism (VTE), but the comparative effectiveness and safety of available prophylactic strategies remain uncertain. A systematic review and meta-analysis of randomized and prospective studies was conducted in accordance with PRISMA 2020. Active thromboprophylaxis is associated with substantially lower VTE incidence than no prophylaxis in patients with multiple myeloma receiving immunomodulatory therapy. 

Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025

Source

Zhang, T., Wang, S., Li, X., Li, X., & Wu, Y. (2026). Global trends in CAR-T cell therapy for multiple myeloma: A bibliometric analysis, 2013–2025. Human Vaccines & Immunotherapeutics, 22(1). https://doi.org/10.1080/21645515.2026.2711554 August 20, 2026. 

Overview

"This study systematically summarizes the global research trends [in CAR T-cell therapy], research hotspots and emerging directions in this field, which provides valuable reference for researchers in this field."

Persistence of M-proteins detected by mass spectrometry

Source

Murray, D.L., Coker, J., Kourelis, T. et al. Persistence of M-proteins detected by mass spectrometry. Blood Cancer J. 16, 140 (2026). https://doi.org/10.1038/s41408- 026-01610-y August 20, 2026. 

Overview

While often thought of as benign, MGUS has long-term implications such as yearly testing and concern for progression to serious disease such as multiple myeloma. Mass spectrometry (MS) detection of monoclonal proteins (M-proteins) is gaining acceptance as a suitable for patient care [2]. The from this study suggest that low-level M-proteins detected by Mass-Fix will persist and are bona-fide MGUS—albeit low risk or even ultra-low risk MGUS. 

Pathogenesis and treatment of extramedullary disease in multiple myeloma: current status, challenges and opportunities

Source

Dong, R., Huang, T., Zhang, W. et al. Pathogenesis and treatment of extramedullary disease in multiple myeloma: current status, challenges and opportunities. J Cancer Res Clin Oncol (2026). https://doi.org/10.1007/s00432-026-06589-4 August 20, 2026. 

Overview

This review integrates recent advances in the molecular pathogenesis of extramedullary disease (EMD) with emerging immunotherapeutic strategies, particularly CAR-T cell-based therapies, and discusses the major translational challenges and future directions for improving the management of EMD. EMD can affect any tissue or organ and is associated with poor clinical outcomes in patients with MM. 

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1

Source

Wang, C., Wang, W., Wang, M. et al. T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1. Cell Death Dis (2026). https://doi.org/10.1038/s41419-026-09190-2 August 21, 2026. 

Overview

Leveraging these biological insights, this study systematically evaluated the capacity of bispecific antibodies to eliminate MM cells via T- cell activation, employing comprehensive in vitro functional assays and in vivo murine models. Meanwhile, PD-L1, an immunosuppressive molecule, is associated with poor prognosis in MM patients. 

RNF6 activates the AKT/mTOR signaling pathway by inhibiting PTEN via K27-linked polyubiquitination in myeloma

Source

Zhong, Yy., Zhang, Lh., Liu, Zy. et al. RNF6 activates the AKT/mTOR signaling pathway by inhibiting PTEN via K27-linked polyubiquitination in myeloma. Acta Pharmacol Sin (2026). https://doi.org/10.1038/s41401-026-01900-y August 21, 2026. 

Overview

In the present study, we find the AKT/mTOR signaling pathway is activated by the ring finger protein RNF6. Consistent with this finding, RNF6 promotes the production of PI(3,4,5)P3, and when PTEN is depleted, RNF6 fails to activate AKT/mTOR signaling. 

Persistence to Multiple Myeloma Treatments Given at First Relapse—Results From the Australian Real-World OPTIMISE Study

Source

F. Buescher, S. Su, B. Waterhouse, and C. Pinto, “Persistence to Multiple Myeloma Treatments Given at First Relapse—Results From the Australian Real-World OPTIMISE Study.” eJHaem 7, no. 4 (2026): e70377. https://doi.org/10.1002/jha2.70377 August 21, 2026. 

Overview

Researchers evaluated real-world persistence to any MM treatment after first relapse before and after DVd availability using the Pharmaceutical Benefits Scheme 10% sample dataset. Treatment persistence in patients who progressed within 18 months on first-line therapy was longer in Period 2 (13 months) than Period 1 (9.2 months) (HR: 0.53; 95% CI: 0.34–0.81; p < 0.01). The observed improvements in treatment persistence among patients with MM including those refractory to lenalidomide, following reimbursement-driven availability of DVd, indicate meaningful clinical benefit in routine practice after the introduction of novel therapies, and underscores the need for sustained access to diverse and effective treatment options for MM.

Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma

Source

Xie, S., Liao, C., Xin, L., Lin, C. Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma. J. Vis. Exp. (234), e69890, doi:10.3791/69890 (2026). August 21, 2026. 

Overview

Researchers validated the assay using cell lines and clinical samples, including residual smears, from patients with Multiple Myeloma (MM). Validation studies in MM patients demonstrated an 81.36% (48/59) concordance rate between multicolor flow cytometry (MFC) and clinical response assessment in tumor cell detection. In conclusion, current evidence supports NGS as a complementary tool to MFC, particularly in MFC/NGS patients, as next-generation sequencing (NGS) offers deeper risk stratification. 

Drug Resistance in Multiple Myeloma: Tumor-Intrinsic Mechanisms and the Bone Marrow Microenvironment

Source

Y. Chen, W. Huang, M. Tang, and X. Wang, “Drug Resistance in Multiple Myeloma: Tumor-Intrinsic Mechanisms and the Bone Marrow Microenvironment,” Cell Biochemistry and Function 44 (2026): e70286, https://doi.org/10.1002/cbf.70286. August 21, 2026. 

Overview

Multiple myeloma (MM) is a malignant plasma cell disorder, and despite substantial improvements in prognosis achieved through chemotherapy, immunotherapy, and autologous stem cell transplantation, most patients ultimately develop relapsed or refractory disease. Researchers highlight how these processes converge on a limited set of survival hubs and collectively raise the apoptotic threshold under therapeutic pressure. 

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma

Source

Dimitrios Tsallos, Nemo Ikonen, Juho J. Miettinen, Muntasir Mamun Majumder, Samuli Eldfors, Imre Västrik, Alun Parsons, Minna Suvela, Katie Dunphy, Paul Dowling, Despina Bazou, Peter O’Gorman, Juha Lievonen, Raija Silvennoinen, Pekka Anttila, Caroline A. Heckman, TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma, iScience, Volume 29, Issue 8, 2026, 116932, ISSN 2589-0042, https://doi.org/10.1016/j.isci.2026.116932. August 21, 2026. 

Overview

TP53 abnormalities contribute to treatment resistance and poor prognosis in multiple myeloma (MM), yet their functional consequences remain unclear. Here, researchers integrate ex vivo drug sensitivity profiling, genomics, transcriptomics, and proteomics across 167 CD138+ bone marrow patient samples to characterize TP53-associated vulnerabilities. Genome-wide CRISPR-Cas9 and RNAi screening identify vulnerabilities in TP53-mutated MM, with or without del(17p), highlighting the dependency on spindle organization, mitotic regulation, DNA synthesis, and transcriptional and metabolic regulation, but independence from MDM2. 

Immune effector cell associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines

Source

Mohan, M., Muddasani, A., Alkhalisy, H. et al. Immune effector cell-associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines. Blood Cancer J. (2026). https://doi.org/10.1038/s41408-026-01611-x August 22, 2026. 

Overview

Most reports on immune effector cell-associated hematotoxicity (ICAHT) originate from CAR T-cell therapies in late-stage MM, with limited data from earlier-line treatment. Researchers conducted a multi-institutional retrospective study of 245 MM patients treated with BCMA CAR T, comparing ICAHT between early-line [early CAR T] (1–3 prior lines; n = 69) and late-line [late CAR T] (≥4 prior lines; n = 176) cohorts. These real-world data show that ICAHT occurs even with earlier-line BCMA CAR T-cell therapy, though less severe, and underscore the prognostic importance of early post-infusion cytopenias. 

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma

Source

Shah, M.R., Bag, A., Shrestha, A. et al. Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma. Blood Cancer J. 16, 141 (2026). https://doi.org/10.1038/s41408-026- 01613-9 August 22, 2026. 

Overview

Bispecific antibodies (bsAbs) targeting B-cell maturation antigen (BCMA) and G protein– coupled receptor class C group 5 member D (GPRC5D) have become important therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM), producing overall response rates of up to 70% [1,2,3,4]. Despite these advances, clinical outcomes remain heterogeneous, and because bispecific antibodies (bsAbs) rely on sustained engagement of immune effector cells, treatment efficacy is dependent on the fitness of the immune compartment. Broadly, these findings suggest that on-treatment lymphocyte kinetics and immune composition may provide prognostic information beyond baseline absolute lymphocyte count (ALC) alone and identify patients at risk for poor outcomes. 

Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis

Source

Suzuki, K., Hanamura, I., Takamatsu, H., Kawamura, K., Sakaida, E., Ri, M., … Tsukada, N. (2026). Prognostic factors of 10-year survival in patients with myeloma after autologous stem cell transplantation: a multicenter retrospective analysis. Leukemia & Lymphoma, 1–11. https://doi.org/10.1080/10428194.2026.2716453 August 23, 2026. 

Overview

Researchers retrospectively analyzed 3650 patients with myeloma who underwent ASCT between 1994 and 2013 using the Japanese Society of Transplantation and Cellular Therapy registry. Prognostic factors for long-term survival (LTS), defined as overall survival (OS) of ≥10 years, remain uncertain among patients with myeloma who undergo autologous stem cell transplantation (ASCT). ISS, HRCA, M-protein subtype, melphalan dose, achieving CR, and post- transplantation therapy were associated with LTS after ASCT. 

Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta-analysis

Source

Shah, V., Shah, D., Utzman, P., Shah, K., Swaminathan, S., Mainou, M., Chakraborty, R., Goodman, A., Al Hadidi, S., Kelkar, A.H., Cliff, E.R.S. and Mohyuddin, G.R. (2026), Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta-analysis. Br J Haematol. https://doi.org/10.1111/bjh.70757 August 23, 2026. 

Overview

By comparison, the development and uptake of ixazomib, the only orally administered proteasome inhibitor, have been mixed, despite ixazomib receiving US Food and Drug Administration (FDA) approval over a decade ago. Despite numerous clinical trials including >6600 patients, many questions regarding ixazomib's clinical utility remain unanswered. After 6689 patients enrolled across 87 trials, ixazomib has not demonstrated overall survival (OS) benefit in a randomized controlled trial (RCT), and its clinical utility remains uncertain. 

Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics

Source

E. Katodritou, B. V. Ferreira, E. Kastritis, et al., “Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics,” American Journal of Hematology (2026): 1–8, https://doi.org/10.1002/ajh.70479. August 24, 2026. 

Overview

The Portuguese validation dataset included 300 patients, of whom 290 were evaluable for the primary overall survival (OS) analysis, with 151 deaths. Established disease-centered prognostic systems may be less tailored to elderly/non- transplant-eligible (NTE) patients with multiple myeloma (MM), in whom host-related factors such as age, performance status, and renal function strongly influence all-cause outcomes. In a baseline score-level Cox model, each ordinal Myeloma Elderly Prognostic Score (MEPS) category increase was associated with inferior OS (HR 1.74, 95% CI 1.58–1.92; p < 0.001). 

Changes in miR-21, miR-32, miR- 181a, and miR-181b expression following treatment and their association with treatment response in multiple myeloma

Source

ALsaadoni, H., Pehlivan, M., Pehlivan, S. et al. Changes in miR-21, miR-32, miR- 181a, and miR-181b expression following treatment and their association with treatment response in multiple myeloma. BMC Cancer (2026). https://doi.org/10.1186/s12885-026-16825-2 August 24, 2026. 

Overview

Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of clonal malignant plasma cells in the bone marrow. This study aimed to evaluate the expression levels of miR-21, miR-32, miR-181a, and miR- 181b in peripheral blood of MM patients before and after treatment, and to investigate the relationship between these miRNAs and clinical treatment response. However, these findings need to be confirmed in larger and independent patient cohorts. 

Real-world multicenter study of thalidomide in NDMM patients in Taiwan

Source

Yun-Chu Lin, Yu-Cheng Chang, Sheng-Wei Fan, Benjamin Tzer-Ming Chuang, Ya-Ting Hsu, Ken-Hong Lim, Kuan-Ming Lai, Ruo-Han Tseng, Hui-Hua Hsiao, Tsai-Yun Chen, Shang-Yi Huang, Real-world multicenter study of thalidomide in NDMM patients in Taiwan, Journal of the Formosan Medical Association, 2026, ISSN 0929-6646, https://doi.org/10.1016/j.jfma.2026.08.041. August 24, 2026. 

Overview

This study evaluates real-world outcomes of thalidomide-based induction and maintenance therapy in Taiwanese NDMM patients. Maintenance therapy plays a critical role in optimizing outcomes for newly diagnosed multiple myeloma (NDMM) patients. These real-world findings support the expanded use of thalidomide maintenance therapy in Taiwan and highlight its potential to provide long-term disease control with manageable toxicity. 

Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid- derived suppressor cells by myeloma cells

Source

Niiyama-Uchibori Y, Tsukamoto T, Inoue Y, Chinen S, Nakamura T, Nagata H, et al. Cellular and molecular impacts of CELMoDs and IMiD on the induction of myeloid- derived suppressor cells by myeloma cells. Br J Haematol. 2026; 00: 1–13. https://doi.org/10.1111/bjh.70787 August 24, 2026. 

Overview

This study aims to identify strategies to prevent the induction of monocytic myeloid-derived suppressor cells (M-MDSCs) in multiple myeloma (MM). Researchers analyzed molecular changes in myeloma and myeloid cells within peripheral blood mononuclear cells (PBMCs) that promote M- MDSC induction during co-culture. CELMoDs effectively inhibit M-MDSC induction by altering gene expression in co-cultured Human Myeloma Cell Lines (HMCLs) and myeloid cells, while also suppressing mediators like IL-10 and Macrophage Migration Inhibitory Factor (MIF). 

Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival

Source

T. Hellou, E. G. Mariotti, A. Alnughmush, et al., “Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival,” American Journal of Hematology (2026): 1–10, https://doi.org/10.1002/ajh.70484. August 24, 2026. 

Overview

Researchers retrospectively evaluated 517 newly diagnosed AL amyloidosis patients seen at Mayo Clinic between 2012 and 2021 who had baseline plasma cell FISH. High-risk abnormalities were identified in 151 patients (29%); +1q accounted for most high-risk (HR) cases (122/151, 81%). These findings suggest that +1q identifies a biologically distinct AL amyloidosis subset characterized by plasma cell–dominant features and inferior long-term disease control. 

Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma

Source

Miranda H Meeuwsen, Anne K. Wouters, Johannes C Wellershoff, Tassilo L.A. Wachsmann, Dennis F.G Remst, Renate S. Hagedoorn, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Els P. van Hees, Masashi Matsuda, Fumihiko Ishikawa, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H. M. Heemskerk; Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma. Blood 2026; blood.2025032234. doi: https://doi.org/10.1182/blood.2025032234 August 24, 2026. 

Overview

This study aims to broaden therapeutic options and overcome antigen escape. Researchers explored T-cell receptor (TCR)-based targeting of intracellular antigens derived from immunoglobulin (Ig) heavy chain constant domains. Despite major progress with chimeric antigen receptor (CAR) T-cell therapy, multiple myeloma (MM) remains largely incurable, and most patients relapse. Collectively, these findings establish immunoglobulin heavy chain constant domains as promising targets for TCR-based cellular immunotherapy in MM and potentially other Ig-producing malignancies or autoantibody-mediated autoimmune diseases. 

A Proliferation Score Defined by PCLI-Anchored Transcriptomics Predicts Outcomes in Multiple Myeloma

Source

Arwa Bohra, Surendra Dasari, Wilson I. Gonsalves, Richard Kandasamy, Prashant Kapoor, Saurabh Zanwar, Moritz Binder, Esteban Braggio, Erik Jessen, Angela Dispenzieri, Michael M Timm, Dragan Jevremovic, S. Vincent Rajkumar, Shaji Kumar, A Proliferation Score Defined by PCLI-Anchored Transcriptomics Predicts Outcomes in Multiple Myeloma, Blood Neoplasia, 2026, 100288, ISSN 2950-3280, https://doi.org/10.1016/j.bneo.2026.100288. August 24, 2026. 

Overview

Using Affymetrix microarray data from 136 MM Mayo Clinic patients with paired plasma cell proliferation measurements, researchers performed a differential expression analysis to identify genes consistently associated with proliferative activity. These genes were subsequently incorporated into a prognostic model development using baseline RNA-seq profiles in purified CD138+ cells from 656 patients in the CoMMpass cohort, where an elastic net-based Cox model yielded an eight-gene Gene-based Proliferation Score (GPS). GPS emerged as an independent prognostic alongside high-risk markers and also predicted S-phase content in an independent dataset. 

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

Source

Facon, T., Kumar, S.K., Orlowski, R.Z. et al. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. Leukemia (2026). https://doi.org/10.1038/s41375-026-03097-9 August 24, 2026. 

Overview

In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). A protocol amendment (July 20, 2021) led to a long- term extension of MAIA, during which patients were followed for OS. With >7 years of follow-up, D-Rd demonstrated a new benchmark for median OS (7.5 years) in transplant- ineligible NDMM, further supporting frontline D-Rd use to maximize survival. 

Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma

Source

M. Bhatt, S. V. Rajkumar, and S. Kumar, “Bispecific Antibodies and T-Cell Engagers in Multiple Myeloma,” European Journal of Haematology (2026): 1–14, https://doi.org/10.1111/ejh.70301. August 25, 2026. 

Overview

In this review, researchers discuss the structure, mechanisms of action, and clinical data for currently approved and emerging T- cell redirecting antibodies and discuss practical questions around sequencing with CAR-T therapy, toxicity mitigation, and resistance. Bispecific antibodies have become indispensable in relapsed myeloma, and for patients who are ineligible for or relapse after CAR-T therapy. Bispecific T-cell engagers have shown high response rates in early relapse, as well as multidrug-refractory disease and post-CAR-T relapse, but are limited by continuous dosing, infections, hypogammaglobulinemia, cytopenias, cytokine release syndrome (CRS), and neurologic toxicity. 

BiRD Regimen Followed by Anti-BCMA CAR-T Cell Immunotherapy as First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 2 Trial

Source

Y. Zhou, J. Chen, Q. Cui, et al., “BiRD Regimen Followed by Anti-BCMA CAR-T Cell Immunotherapy as First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 2 Trial,” American Journal of Hematology (2026): 1– 6, https://doi.org/10.1002/ajh.70485. August 25, 2026. 

Overview

Novel agents such as proteasome inhibitors (PI), immunomodulatory drugs (IMIDs), and monoclonal antibodies have significantly improved the outcomes of patients with multiple myeloma (MM). However, it remains an incurable disease since most MM patients eventually relapse due to clonal evaluation or drug resistance. In summary, the BiRD regimen followed by BCMA CAR-T cell therapy represents a promising front-line treatment option that demonstrated rapid deep remission while maintaining a favorable safety profile for NDMM patients. 

Exploratory analysis of a novel obesity-related gene- based prognostic model as a potential prognostic biomarker in multiple myeloma

Source

Hong, H., Qin, Y., Lin, G. et al. Exploratory analysis of a novel obesity-related gene- based prognostic model as a potential prognostic biomarker in multiple myeloma. Discov Onc (2026). https://doi.org/10.1007/s12672-026-05646-1 August 25, 2026. 

Overview

This study aimed to elucidate the genetic interplay between obesity and multiple myeloma (MM) and to develop a novel obesity-related gene-based prognostic model using an integrated multi-omics framework combining single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (RNA-seq). A differential expression analysis of the GSE132604 exploratory discovery cohort was performed using the limma package to identify obesity-related differentially expressed genes (DEGs). This study developed a novel obesity-related gene-based prognostic model that reliably predicts survival outcomes in MM and provides a multi-omics foundation for risk stratification and future precision-medicine studies in MM. 

Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma

Source

Tauro, M., Li, T., Sudalagunta, P.R. et al. Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma. Nat Commun (2026). https://doi.org/10.1038/s41467-026-76711-0 August 25, 2026. 

Overview

This study analyzes RNA sequencing data from CD138 + MM patient cells (n = 813) across disease stages and identifies an autophagy gene signature. Despite effective therapies such as proteasome inhibitors, multiple myeloma (MM) patients relapse with refractory disease. These findings implicate ULK3-associated autophagy in MM progression and support further evaluation of ULK3-directed kinase inhibition as a therapeutic strategy in newly diagnosed and refractory MM. 

Beyond the M-spike - Immunoparesis and Multiple Myeloma. A narrative review

Source

Elizabeth Sarah Mayne, Catherine Mary Worsley, Tracey Monica Wiggill, Beyond the M-spike - Immunoparesis and Multiple Myeloma. A narrative review, Immunology Letters, 2026, 107236, ISSN 0165-2478, https://doi.org/10.1016/j.imlet.2026.107236. August 25, 2026. 

Overview

Although classically described as a reduced production of polyclonal immunoglobulins, MM induces global immune dysfunction with defects in innate immune and T cell effector function. Patients with immunoparesis have a poorer prognosis and present with severe, recurrent infections, which are associated with increased morbidity and mortality, especially in the first 3 months following diagnosis, with relapse or progression, and with the use of novel therapeutics. Although vaccination against encapsulated organisms, reactivating viruses, and circulating seasonal viruses is recommended, the response in MM may be suboptimal. 

Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma

Source

Fonseca, R., Brunner, M. J., Fanning, S., Nahas, G., Nagar, S. P., De Wiest, D., … Qureshi, Z. P. (2026). Real-world treatment patterns and outcomes of patients treated with commercial chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma. Current Medical Research and Opinion, 1–7. https://doi.org/10.1080/03007995.2026.2717477 August 25, 2026. 

Overview

This study aims to characterize physician-reported prescribing patterns and referral pathways for chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed/refractory multiple myeloma (RRMM), and to describe treatment patterns and clinical outcomes among patients receiving commercial ciltacabtagene autoleucel (cilta-cel). This study comprised a descriptive physician survey and retrospective medical chart review. This real-world study adds to the body of evidence on decision-making for use of commercial CAR-T therapies and supports the development of clinical best practices and guidelines, payer decisions, and health system planning for CAR-T treatment in RRMM. 

Adrenergic stimulation of bone marrow immunity differentially affects myeloma growth and immunotherapy responses

Source

Hatice Satilmis, Emma Verheye, Sylvia Faict, Robbe Heestermans, Ann De Becker, Karin Vanderkerken, Elke De Bruyne, Eline Menu, Erica K. Sloan, Kim De Veirman, Adrenergic stimulation of bone marrow immunity differentially affects myeloma growth and immunotherapy responses, Cancer Letters, 2026, 218802, ISSN 0304-3835, https://doi.org/10.1016/j.canlet.2026.218802. August 25, 2026. 

Overview

Using the 5T33MM mouse model, researchers investigated how adrenergic activation affects tumor growth and the bone marrow immune landscape. Immune composition and tumor burden were analyzed in bone marrow and spleen, β2-adrenergic receptor expression was examined across murine and human immune populations, and ex vivo assays were performed using murine and patient-derived bone marrow samples treated with adrenergic agonists alone or combined with relevant myeloma immunotherapies. Chronic restraint stress remodeled the bone marrow immune compartment in MM-bearing mice, characterized by expansion of innate effector populations, including neutrophils and natural killer cells, and it was associated with a significant reduction in bone marrow tumor burden. 

Comprehensive Analyses of SOX7 Provide Novel Insights on Its Tumor Suppressor Role and Its Target Genes with Therapeutic Implications in Multiple Myeloma

Source

Ceylan, A., Hu, X., Hatipoğlu, T., Nainkwi, F. C., Payzın, K. B., Özsan, G. H., Demiriz, I. Ş., Şeker, Ö., Kakçı, M., Öztürk, O. C., Yılmaz, B., Yıldız, E., Pavlopoulou, A., & Küçük, C. (2026). Comprehensive Analyses of SOX7 Provide Novel Insights on Its Tumor Suppressor Role and Its Target Genes with Therapeutic Implications in Multiple Myeloma. International Journal of Molecular Sciences, 27(17), 7648. https://doi.org/10.3390/ijms27177648.&nbsp;

Overview

Researchers characterized SOX7 through genetic, epigenetic, and functional analyses in MM cell lines. Flow cytometric analysis of permeabilized bone marrow tumor cells from newly diagnosed and relapsed MM patients demonstrated generally low SOX7 protein expression. 

Engineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma

Source

Minchuan Zhang, Wai Fook Leong, Jianxin Huo, Eve Zi Xian Ngoh, Hanping Loh, Qingfeng Chen, Sabrina H. M. Toh, Sanjay De Mel, Melissa Ooi, Cinnie Soekojo, Wee Joo Chng, Yuansheng Yang, Kong-Peng Lam, Shengli Xu; Engineering a TACI × CD3 bispecific antibody to redirect T cells against multiple myeloma. Blood Adv 2026; 10 (16): 5669–5682. doi: https://doi.org/10.1182/bloodadvances.2025018210 August 25, 2026. 

Overview

In this study, researchers developed a T-cell–redirecting bispecific antibody (bsAb) targeting transmembrane activator and CAML interactor (TACI), another tumor necrosis factor receptor (TNFR) superfamily member expressed on MM cells. However, a major challenge is the frequent downregulation or loss of BCMA expression in patients receiving BCMA-targeted immunotherapies, which substantially diminishes therapeutic efficacy and contributes to disease progression and treatment resistance after an initial positive response. Collectively, these findings suggest that TACI-targeted T-cell–redirecting bsAb may represent a promising therapeutic strategy for MM, with the potential of overcoming resistance associated with BCMA downregulation in MM. 

EZH2-dependent STAT3 stabilization drives pomalidomide resistance and is targetable by EZH2 inhibition in multiple myeloma

Source

Zhang X, Hu R, Hu K, Li Q, Qin L, Chai Y, Zhuang W, Zhang X. EZH2-dependent STAT3 stabilization drives pomalidomide resistance and is targetable by EZH2 inhibition in multiple myeloma. Acta Biochim Biophys Sin (Shanghai). 2026 Aug 26. doi: 10.3724/abbs.2026112. Epub ahead of print. 

Overview

Relapsed/refractory multiple myeloma (RRMM) is characterized by high mortality rates and limited survival, with real-world studies reporting substantial mortality and median survival of only a few years after relapse. In this study, the analysis of public datasets identifies significant upregulation of enhancer of zeste homolog 2 (EZH2) in RRMM patients, together with an association between EZH2 expression and poor prognosis. Researchers found that EZH2 contributes to pomalidomide resistance through stabilizing STAT3 protein, thereby supporting myeloma cell survival under therapeutic stress. 

Consensus- based recommendations by the Hematology Society of Taiwan for the management of multiple myeloma in 2026

Source

Yu-Chin Hung, Shih-Feng Cho, Yi-Yang Chen, Ya-Ting Hsu, Shang-Yi Huang, Chao-Hung Wei, Chun-Kuang Tsai, Wei-Han Huang, Chia-Jen Liu, Consensus- based recommendations by the Hematology Society of Taiwan for the management of multiple myeloma in 2026, Journal of the Formosan Medical Association, 2026, ISSN 0929-6646, https://doi.org/10.1016/j.jfma.2026.08.029. August 26, 2026. 

Overview

Multiple myeloma (MM) presents a growing challenge in Taiwan's aging population, necessitating practical treatment strategies that integrate clinical evidence with real-world constraints. These guidelines outline diagnostic standards based on the IMWG criteria and risk stratification, offering alternative monitoring approaches when serial FISH, PET-CT, or MRD testing is unavailable. 

Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability

Source

Horigome, Y., Ehata, K., Tadera, N. et al. Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability. Blood Res. 61, 47 (2026). https://doi.org/10.1007/s44313-026-00165-y August 26, 2026. 

Overview

This study aims to evaluate the effectiveness, treatment durability, and infectious complications of frontline daratumumab, lenalidomide, and dexamethasone (DRd) in patients aged > 80 years with transplant-ineligible newly diagnosed multiple myeloma (Ti-NDMM) and to explore associations between baseline nutritional vulnerability and treatment outcomes. Researchers retrospectively analyzed consecutive patients aged > 80 years with Ti-NDMM who received frontline DRd. Exploratory analyses suggested that a lower baseline prognostic nutritional index (PNI) may be associated with severe infectious complications and shorter treatment durability. 

Real- world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

Source

Strassl I, Nikoloudis A, Ruesing LZ, Melchardt T, Leisch M, Schulz E, et al. Real- world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria. Br J Haematol. 2026; 00: 1–11. https://doi.org/10.1111/bjh.70773 August 26, 2026. 

Overview

Researchers performed a nationwide retrospective real-world analysis (RWA) of Austrian patients treated with ide-cel or cilta-cel between January 2024 and July 2025. However, no randomized head-to-head comparison of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) is available, and real-world data suggest differences in efficacy and toxicity. Researchers support further investigation of optimal bridging strategies and treatment sequencing while highlighting the persistent unmet need of patients with true extramedullary disease (EMD). 

Interim analysis in clinical trials: caution against premature conclusions—the SWOG multiple myeloma S0777 case study

Source

Goren, E., Sexton, R., Orlowski, R.Z. et al. Interim analysis in clinical trials: caution against premature conclusions—the SWOG multiple myeloma S0777 case study. Trials 27, 550 (2026). https://doi.org/10.1186/s13063-026-09969-w August 27, 2026. 

Overview

Such analyses as this one can accelerate access to effective therapies and limit exposure to ineffective ones, but this must be weighed against premature closure that can risk obscuring a true treatment benefit. Interim monitoring for efficacy and futility provides critical decision-making boundaries on early termination of randomized clinical trials. In contrast, at final analysis, VRd demonstrated significant improvement in both PFS (hazard ratio (HR) = 0.71, p = 0.0018) and overall survival (HR = 0.71, p = 0.025) compared to Rd, helping establish VRd as standard of care.

CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8+ T cells

Source

Zhang, C., Wei, Q., Rahim, N. et al. CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8+ T cells. Cancer Gene Ther (2026). https://doi.org/10.1038/s41417-026-01078-9 August 27, 2026. 

Overview

This study aims to improve the therapeutic outcome, this study investigated the combined treatment of selinexor and a CD73 inhibitor in a murine tumor model. The study demonstrated that selinexor treatment upregulated CD73 expression in the majority of tumors. Nevertheless, selinexor presents limited monotherapy efficacy with a response rate of 29% and fails to completely overcome drug resistance.  

Targeting METTL3/m6A/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma

Source

Wang, G., Zhou, F., Yan, X. et al. Targeting METTL3/m6A/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma. Cell. Mol. Life Sci. (2026). https://doi.org/10.1007/s00018- 026-06421-9 August 27, 2026. 

Overview

This study investigated the immunomodulatory roles of suppressor of cytokine signaling 3 (SOCS3) in macrophage polarization and cytotoxic T-cell activation within the tumor microenvironment (TME) of multiple myeloma (MM). Additionally, the antitumor efficacy of combined SOCS3 overexpression and anti- programmed cell death protein 1 (anti-PD-1) therapy was evaluated in a syngeneic subcutaneous tumor mouse model. Combining SOCS3 restoration with anti-PD-1 therapy provides a preclinical proof-of-concept for potential combinatorial strategies to enhance immune responses in MM. 

Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma

Source

Crusoé, E.Q., Ribeiro, G., Souto Filho, J.T.D., Schmidt Filho, J., Schutz, N., Aranha, M.A.F., Costa, A., Hallack, A., Pericole, F.V., Lima, J.S., Gusmão, B., Ribeiro, E.F.O., Vaz, J.P., Bittencourt, R., Cunha, R., Ovigli, D., Berg, L., Mattos, E.R., Maiolino, A., Hungria, V. and GBRAM (2026), Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma. Br J Haematol. https://doi.org/10.1111/bjh.70775 August 27, 2026. 

Overview

An indirect comparison between daratumumab with bortezomib, lenalidomide and dexamethasone (Dara-VRd) and daratumumab-lenalidomide (Dara-Len) maintenance with daratumumab with bortezomib, thalidomide and dexamethasone (Dara- VTd) and Dara/observation revealed superior efficacy for the Dara-VRd-based regimen, complete response (CR) (87.9% vs.39%). Although lenalidomide maintenance is widely used after Dara-VTd in routine practice, no randomized study has evaluated this sequence. This study provides robust real-world evidence supporting already widespread clinical practice and guides therapeutic decisions while we await direct comparative studies to define the optimal maintenance strategy in the era of anti-CD38-based quadruplet induction therapies. 

Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study

Source

Gautam, N., Kandel, K., & Sharma, J. (2026). Statin exposure after multiple myeloma diagnosis and risk of all-cause mortality, venous thromboembolism, pathological fractures, and acute kidney injury: a propensity score-matched retrospective cohort study. Annals of Medicine & Surgery, 88(8), 4854–4865. https://doi.org/10.1097/MS9.0000000000005281 August 2026. 

Overview

Statins possess anti- inflammatory, immunomodulatory, and anti-thrombotic properties that may reduce these complications, yet their associations with several key MM outcomes have not been evaluated simultaneously in a single real-world cohort. Researchers conducted a retrospective cohort study in the TriNetX Linked network (query date: 16 January 2026). In this propensity score-matched electronic health record cohort study, statin exposure after MM diagnosis was associated with improved 5-year survival and fewer VTEs and pathological fractures, with a modest time-to-event benefit for AKI. 

Translocation t(11;14) and BCL2-inhibition in multiple myeloma

Source

Sim S, Dhakal B, Quach H. Translocation t(11;14) and BCL2-inhibition in multiple myeloma. Haematologica 2026; 111(8):2578-2590; https://doi.org/10.3324/haematol.2025.289147. August 2026. 

Overview

Multiple myeloma is an increasingly treatable disease with improved survival, although characterized by multiple subclones that drive heterogeneity and variable clinical outcomes between patients. A biomarker-driven approach can help to tailor treatment and improve patient outcomes. This review examines the pathogenesis and prognostic significance of t(11;14) in myeloma and the impact of concurrent high-risk cytogenetics, the mechanism of action of BCL2-inhibitors, cumulative evidence supporting their use, and proposed mechanisms of resistance. 

Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database

Source

Muni Rubens, Jeremy Purow, Daniel M. Portnoy, Alejandra Viera Plasencia, Julia Steger, Sofia Steger, Feng Go Ho Wu, Jorge Valdés, Vicente Abreu Fernández, Vicente Gea Caballero, Sandra Sepúlveda, Paolo Cháves, Marco A Ruiz Andia, Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database, Current Problems in Cancer, Volume 63, 2026, 101299, ISSN 0147-0272, https://doi.org/10.1016/j.currproblcancer.2026.101299. August 2026. 

Overview

Researchers conducted a retrospective analysis using data from the National Cancer Database (NCDB) collected between 2004 and 2021. This study highlights the vital role of personalized treatment strategies in managing multiple myeloma (MM) among older patients, a population greatly affected by this disease. Furthermore, extended treatment duration—particularly beyond 180 days—was linked to improved survival, supporting maintenance and continuous therapy approaches. 

Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia

Source

Hong Li, Timothy Wong, Arefeh Rouhi, Yasser Abou-Mourad, Hannah Cherniawsky, Shanee Chung, Donna Forrest, Deepesh Lad, Stephen Nantel, Sujaatha Narayanan, Thomas Nevill, Anna Nguyen, Afsaneh Panahi, Melika Bakharzi, Stephen Parkin, Claudia Piechnik, Judith Rodrigo, Claudie Roy, David Sanford, Ryan J. Stubbins, Cynthia Toze, Julia Varghese, Jennifer White, Edward Wong, Heather Sutherland, Kevin Song, Chris P. Venner, Florian Kuchenbauer, Determinants of clinical trial participation in multiple myeloma: A population-based cohort study from British Columbia, Leukemia Research, Volume 167, 2026, 108254, ISSN 0145-2126, https://doi.org/10.1016/j.leukres.2026.108254. August 2026. 

Overview

Demographic, clinical, geographic, and socioeconomic variables, including area-level measures of deprivation, were compared between groups. The extent to which these factors shape trial participation and whether participation is independently associated with overall survival (OS) in real-world MM populations remain uncertain, particularly within centralized healthcare systems. Trial participants were more likely to reside closer to the treating center, live in urban areas, and demonstrate better performance status and lower comorbidity burden. 

Multiple myeloma mortality in Latin America: Heterogeneous patterns and challenges in cross- country comparisons

Source

Bryan Valcarcel, Eloísa Riva, Camila Peña, Alana von Glasenapp, Veronica Leautaud, Luis Malpica, Michelle A.T. Hildebrandt, Multiple myeloma mortality in Latin America: Heterogeneous patterns and challenges in cross- country comparisons, Cancer Epidemiology, Volume 103, 2026, 103103, ISSN 1877-7821, https://doi.org/10.1016/j.canep.2026.103103. August 2026. 

Overview

Differences in death certification practices may affect cross-country comparisons of multiple myeloma (MM) mortality estimates. In this population-based study, we analyzed mortality data from 15 Latin American countries (World Health Organization Mortality Database) and the US (National Center for Health Statistics data). Stratified analyses by sex showed similar findings. 

Occupational pesticide exposure and association of monoclonal gammopathy of undetermined significance in the Western Macroregion of Paraná

Source

Ana Flávia Redolfi Oliota, Mayara Pryscila Borsa, Ademar Dantas da Cunha Junior, Maria Lúcia Frizon Rizzotto, Occupational pesticide exposure and association of monoclonal gammopathy of undetermined significance in the Western Macroregion of Paraná, Cancer Epidemiology, Volume 103, 2026, 103119, ISSN 1877-7821, https://doi.org/10.1016/j.canep.2026.103119. August 2026. 

Overview

This analytical observational study with a cross-sectional design assessed the prevalence of MGUS and its association with occupational pesticide exposure among men aged 50 years or older in the Western Macroregion of Paraná, Brazil. These findings should be interpreted with caution due to the cross-sectional design and limited number of MGUS cases, but contribute to the existing evidence on MGUS prevalence in populations with occupational pesticide exposure and highlight the need for further longitudinal studies.